TEN-YEAR SELECTED FINANCIAL DATA
(Dollar amounts in thousands except per share amounts)
Years Ended December 31, 2002 2001 2000
- -------------------------------------------------------------------------------------------------------------------
SUMMARY OF NET REVENUE AND EARNINGS
Net revenue(1)(2) $14,584,035 $13,983,745 $ 13,081,334
Income (loss) from continuing operations (2)(3)(5) 4,447,205 2,285,294 (901,040)
Diluted earnings (loss) per share from continuing operations(2)(3)(4) 3.33 1.72 (0.69)
Dividends per common share 0.9200 0.9200 0.9200
YEAR-END FINANCIAL POSITION
Current assets(2)(5) $11,595,852 $ 9,766,753 $ 10,180,811
Current liabilities(2)(5) 5,475,659 7,257,181 9,742,059
Ratio of current assets to current liabilities(2)(5) 2.12 1.35 1.05
Total assets(2)(5) 25,994,949 22,967,922 21,092,466
Long-term debt(2)(6) 7,546,041 7,357,277 2,394,790
Average stockholders' equity 6,114,243 3,445,333 4,516,420
STOCKHOLDERS - OUTSTANDING SHARES
Number of common stockholders 61,668 64,698 58,355
Weighted average common shares outstanding used for
diluted earnings (loss) per share calculation (in thousands)(4) 1,334,127 1,330,809 1,306,474
EMPLOYMENT DATA(2)
Number of employees at year-end 52,762 52,289 48,036
Wages and salaries $ 2,792,379 $ 2,536,220 $ 2,264,258
Benefits (including Social Security taxes) 842,177 691,018 602,816
(1) The Company adopted new authoritative accounting guidance as of January 1,
2002 reflecting the cost of certain vendor considerations (i.e.,
cooperative advertising payments) as reductions of revenues instead of
selling and marketing expenses. Net revenue for all prior periods
presented has been reclassified to comply with the income statement
classification requirements of the new guidance.
(2) As a result of the sale of the Cyanamid Agricultural Products business on
June 30, 2000, amounts for the years 1994 through 1999 were restated to
reflect this business as a discontinued operation with the net assets of
the discontinued business held for sale related to the Cyanamid
Agricultural Products business included in current assets.
(3) See "Management's Discussion and Analysis of Financial Condition and
Results of Operations" for discussion of: gains related to Immunex/Amgen
common stock transactions, termination fee, litigation charges, goodwill
impairment and special charges for the years ended December 31, 2002, 2001
and 2000.
(4) The weighted average common shares outstanding for diluted loss per share
for 2000 and 1999 did not include common stock equivalents, as the effect
would have been antidilutive.
(5) As a result of the litigation charges of $1,400,000, $950,000, $7,500,000
and $4,750,000 in 2002, 2001, 2000 and 1999, respectively, related to the
litigation brought against the Company regarding the use of the diet drugs
Redux or Pondimin, current liabilities increased substantially in 2000 and
1999 compared with prior years and unfavorably impacted the ratio of
current assets to current liabilities in years subsequent to 1998.
In 2002, the Company sold 67,050,400 shares of Amgen Inc. (Amgen) common
stock received in connection with Amgen's acquisition of Immunex
Corporation (Immunex) for net proceeds of $3,250,753. The Company used a
portion of these proceeds to pay down commercial paper and substantially
reduce current liabilities. Additionally, the remaining 31,235,958 shares
of Amgen common stock owned by the Company as of December 31, 2002 had a
fair value of $1,509,947. The fair value of these shares as well as the
proceeds from the shares sold in 2002 substantially increased total
assets.
(6) In 2001, the Company obtained a $3,000,000 credit facility to support
increased commercial paper borrowings and issued $3,000,000 of Senior
Notes. The proceeds from these borrowings were used for the Company's
general corporate and working capital requirements, including payments
related to the Redux and Pondimin diet drug litigation.
(7) The 1994 information reflects the acquisition of American Cyanamid Company
for the one-month period ended December 31, 1994.
26 Wyeth
1999 1998 1997 1996 1995 1994(7) 1993
- ------------------------------------------------------------------------------------------------------------
$ 11,695,061 $11,101,100 $11,916,623 $11,928,290 $11,274,927 $ 8,597,560 $8,035,277
(1,207,243) 2,152,344 1,747,638 1,651,617 1,472,525 1,525,517 1,469,300
(0.92) 1.61 1.33 1.28 1.18 1.24 1.17
0.9050 0.8700 0.8300 0.7825 0.7550 0.7350 0.7150
$ 12,384,778 $10,698,188 $10,025,512 $10,310,256 $11,084,841 $11,321,682 $4,807,684
6,480,383 3,478,119 3,476,322 3,584,256 3,929,940 4,291,452 1,584,411
1.91 3.08 2.88 2.88 2.82 2.64 3.03
23,123,756 20,224,231 19,851,517 19,924,666 20,721,093 21,328,267 7,687,353
3,606,423 3,839,402 5,007,610 6,010,297 7,806,717 9,972,444 859,278
7,914,772 8,895,024 7,568,672 6,252,545 4,898,550 4,065,295 3,719,539
62,482 65,124 64,313 67,545 68,763 71,223 72,664
1,308,876 1,336,641 1,312,975 1,287,790 1,250,902 1,234,100 1,252,990
46,815 47,446 54,921 54,194 58,957 70,300 51,399
$ 2,032,431 $ 2,175,517 $ 2,428,518 $ 2,439,604 $ 2,512,418 $ 1,811,402 $1,654,984
593,222 577,930 619,528 614,179 641,169 439,572 396,045
Wyeth 27
CONSOLIDATED BALANCE SHEETS
(In thousands except share and per share amounts)
December 31, 2002 2001
- -----------------------------------------------------------------------------------
ASSETS
Cash and cash equivalents $ 2,943,604 $ 1,744,734
Marketable securities 1,003,275 1,281,988
Amgen investment 1,509,947 --
Accounts receivable less allowances
(2002 - $132,342 and 2001 - $130,734) 2,379,819 2,743,040
Inventories 1,992,724 1,754,971
Other current assets including deferred taxes 1,766,483 2,242,020
- -----------------------------------------------------------------------------------
TOTAL CURRENT ASSETS 11,595,852 9,766,753
Property, plant and equipment:
Land 173,743 138,837
Buildings 3,401,490 3,294,004
Machinery and equipment 3,782,533 3,796,117
Construction in progress 2,477,219 1,715,493
- -----------------------------------------------------------------------------------
9,834,985 8,944,451
Less accumulated depreciation 2,599,293 2,662,291
- -----------------------------------------------------------------------------------
7,235,692 6,282,160
Goodwill 3,745,749 3,725,547
Other intangibles, net of accumulated amortization
(2002 - $95,223 and 2001 - $71,070) 145,915 126,387
Other assets including deferred taxes 3,271,741 3,067,075
- -----------------------------------------------------------------------------------
TOTAL ASSETS $ 25,994,949 $ 22,967,922
===================================================================================
- -----------------------------------------------------------------------------------
LIABILITIES
Loans payable $ 804,894 $ 2,097,354
Trade accounts payable 672,633 672,457
Accrued expenses 3,788,653 4,257,523
Accrued federal and foreign taxes 209,479 229,847
- -----------------------------------------------------------------------------------
TOTAL CURRENT LIABILITIES 5,475,659 7,257,181
Long-term debt 7,546,041 7,357,277
Accrued postretirement benefit obligations
other than pensions 965,081 925,098
Other noncurrent liabilities 3,852,256 3,355,793
Contingencies and commitments (Note 14)
- -----------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------
STOCKHOLDERS' EQUITY
$2.00 convertible preferred stock, par value
$2.50 per share; 5,000,000
shares authorized 46 51
Common stock, par value $0.331/3 per share;
2,400,000,000 shares authorized
(outstanding shares: 2002 - 1,326,055,000
and 2001 - 1,320,570,000) 442,019 440,190
Additional paid-in capital 4,582,773 4,295,051
Retained earnings 3,286,645 170,309
Accumulated other comprehensive loss (155,571) (833,028)
- -----------------------------------------------------------------------------------
TOTAL STOCKHOLDERS' EQUITY 8,155,912 4,072,573
- -----------------------------------------------------------------------------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 25,994,949 $ 22,967,922
===================================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
28 Wyeth
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands except per share amounts)
Years Ended December 31, 2002 2001 2000
- --------------------------------------------------------------------------------------------------------------
NET REVENUE $ 14,584,035 $ 13,983,745 $ 13,081,334
- --------------------------------------------------------------------------------------------------------------
Cost of goods sold 3,918,387 3,388,776 3,269,418
Selling, general and administrative expenses 5,010,507 5,034,516 4,851,128
Research and development expenses 2,080,191 1,869,679 1,687,889
Interest expense, net 202,052 146,358 57,562
Other income, net (382,931) (274,331) (161,039)
Gains related to Immunex/Amgen common stock transactions (4,082,216) -- (2,061,204)
Termination fee -- -- (1,709,380)
Litigation charges 1,400,000 950,000 7,500,000
Goodwill impairment -- -- 401,000
Special charges 340,800 -- 347,000
- --------------------------------------------------------------------------------------------------------------
Income (loss) from continuing operations before
federal and foreign taxes 6,097,245 2,868,747 (1,101,040)
Provision (benefit) for federal and foreign taxes 1,650,040 583,453 (200,000)
- --------------------------------------------------------------------------------------------------------------
INCOME (LOSS) FROM CONTINUING OPERATIONS 4,447,205 2,285,294 (901,040)
Discontinued operations:
Income from operations of discontinued agricultural
products business (net of federal and foreign taxes
of $57,289) -- -- 103,346
Loss on disposal of agricultural products business
(net of federal and foreign taxes of $855,248) -- -- (1,572,993)
- --------------------------------------------------------------------------------------------------------------
LOSS FROM DISCONTINUED OPERATIONS -- -- (1,469,647)
- --------------------------------------------------------------------------------------------------------------
NET INCOME (LOSS) $ 4,447,205 $ 2,285,294 $ (2,370,687)
==============================================================================================================
BASIC EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS $ 3.35 $ 1.74 $ (0.69)
BASIC LOSS PER SHARE FROM DISCONTINUED OPERATIONS -- -- (1.12)
- --------------------------------------------------------------------------------------------------------------
BASIC EARNINGS (LOSS) PER SHARE $ 3.35 $ 1.74 $ (1.81)
==============================================================================================================
DILUTED EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS $ 3.33 $ 1.72 $ (0.69)
DILUTED LOSS PER SHARE FROM DISCONTINUED OPERATIONS -- -- (1.12)
- --------------------------------------------------------------------------------------------------------------
DILUTED EARNINGS (LOSS) PER SHARE $ 3.33 $ 1.72 $ (1.81)
==============================================================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
Wyeth 29
CONSOLIDATED STATEMENTS OF
CHANGES IN STOCKHOLDERS' EQUITY
(In thousands except per share amounts)
$2.00 RETAINED ACCUMULATED
CONVERTIBLE ADDITIONAL EARNINGS OTHER TOTAL
PREFERRED COMMON PAID-IN (ACCUMULATED COMPREHENSIVE STOCKHOLDERS'
STOCK STOCK CAPITAL DEFICIT) LOSS EQUITY
- ----------------------------------------------------------------------------------------------------------------------------------
Balance at January 1, 2000 $ 61 $ 434,639 $ 3,392,705 $ 3,000,827 $(613,485) $ 6,214,747
- ----------------------------------------------------------------------------------------------------------------------------------
Net Loss (2,370,687) (2,370,687)
Currency translation adjustments (70,496) (70,496)
Unrealized gains on marketable securities 11,422 11,422
-----------
Comprehensive loss, net of tax (2,429,761)
-----------
Cash dividends declared:
Preferred stock (per share: $2.00) (46) (46)
Common stock (per share: $0.92) (1,201,431) (1,201,431)
Common stock acquired for treasury (2,472) (16,316) (374,289) (393,077)
Common stock issued for stock options 4,949 405,933 410,882
Conversion of preferred stock
and other exchanges (6) 142 170,135 (6,663) 163,608
International operations year-end change 53,171 53,171
- ----------------------------------------------------------------------------------------------------------------------------------
BALANCE AT DECEMBER 31, 2000 55 437,258 3,952,457 (899,118) (672,559) 2,818,093
==================================================================================================================================
- ----------------------------------------------------------------------------------------------------------------------------------
Net income 2,285,294 2,285,294
Currency translation adjustments (166,200) (166,200)
Unrealized gains on derivative contracts 7,865 7,865
Unrealized losses on marketable securities (2,134) (2,134)
-----------
Comprehensive income, net of tax 2,124,825
-----------
Cash dividends declared:
Preferred stock (per share: $2.00) (42) (42)
Common stock (per share: $0.92) (1,211,012) (1,211,012)
Common stock issued for stock options 2,774 221,857 224,631
Conversion of preferred stock and other
exchanges (4) 158 120,737 (4,813) 116,078
- ----------------------------------------------------------------------------------------------------------------------------------
BALANCE AT DECEMBER 31, 2001 51 440,190 4,295,051 170,309 (833,028) 4,072,573
==================================================================================================================================
- ----------------------------------------------------------------------------------------------------------------------------------
Net income 4,447,205 4,447,205
Currency translation adjustments 226,797 226,797
Unrealized losses on derivative contracts (22,132) (22,132)
Unrealized gains on marketable securities 520,483 520,483
Minimum pension liability adjustments (47,691) (47,691)
-----------
Comprehensive income, net of tax 5,124,662
-----------
Cash dividends declared:
Preferred stock (per share: $2.00) (38) (38)
Common stock (per share: $0.92) (1,219,135) (1,219,135)
Common stock acquired for treasury (667) (5,472) (107,788) (113,927)
Common stock issued for stock options 2,349 213,021 215,370
Conversion of preferred stock and other
exchanges (5) 147 80,173 (3,908) 76,407
- ----------------------------------------------------------------------------------------------------------------------------------
BALANCE AT DECEMBER 31, 2002 $ 46 $ 442,019 $ 4,582,773 $ 3,286,645 $(155,571) $ 8,155,912
==================================================================================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
30 Wyeth
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Years Ended December 31, 2002 2001 2000
- -------------------------------------------------------------------------------------------------------------
OPERATING ACTIVITIES
Income (loss) from continuing operations $ 4,447,205 $ 2,285,294 $ (901,040)
Adjustments to reconcile income (loss) from continuing
operations to net cash provided by/(used for) operating
activities of continuing operations:
Litigation charges 1,400,000 950,000 7,500,000
Gains related to Immunex/ Amgen common stock transactions (4,082,216) -- (2,061,204)
Goodwill impairment -- -- 401,000
Special charges 340,800 -- 347,000
Gains on sales of assets (329,364) (249,399) (159,430)
Depreciation 461,554 426,590 336,239
Amortization 23,146 181,139 198,810
Deferred income taxes 1,109,535 267,820 (814,282)
Diet drug litigation payments (1,307,013) (7,257,882) (3,966,845)
Security fund deposit (405,000) -- --
Contributions to defined benefit pension plans (909,602) (429,710) (17,554)
Deconsolidation of Immunex -- -- (236,768)
Changes in working capital, net of businesses
sold or deconsolidated:
Accounts receivable 271,988 (68,984) (433,182)
Inventories (185,611) (273,063) 31,188
Other current assets (124,738) (395,764) 179,817
Trade accounts payable and accrued expenses (250,887) 277,009 270,518
Accrued federal and foreign taxes (33,214) (14,654) (393,330)
Other items, net (240,853) (145,231) 196,405
- -------------------------------------------------------------------------------------------------------------
Net cash provided by/(used for) continuing operations 185,730 (4,446,835) 477,342
Net cash provided by discontinued operations -- -- 77,600
- -------------------------------------------------------------------------------------------------------------
NET CASH PROVIDED BY/(USED FOR) OPERATING ACTIVITIES 185,730 (4,446,835) 554,942
=============================================================================================================
- -------------------------------------------------------------------------------------------------------------
Investing Activities
Purchases of property, plant and equipment (1,931,879) (1,924,265) (1,681,906)
Proceeds from sale of agricultural products business -- -- 3,800,000
Proceeds from Amgen acquisition of Immunex 1,005,201 -- --
Proceeds from sales of Immunex/Amgen common stock 3,250,753 -- 2,404,875
Proceeds from sales of assets 798,274 408,230 256,192
Purchases of marketable securities (2,235,872) (2,703,252) (677,802)
Proceeds from sales and maturities of marketable securities 2,532,538 1,762,295 384,292
- -------------------------------------------------------------------------------------------------------------
NET CASH PROVIDED BY/(USED FOR) INVESTING ACTIVITIES 3,419,015 (2,456,992) 4,485,651
=============================================================================================================
- -------------------------------------------------------------------------------------------------------------
Financing Activities
Net proceeds from/(repayments of) debt (1,293,857) 7,007,156 (3,080,381)
Dividends paid (1,219,173) (1,211,054) (1,201,477)
Purchases of common stock for treasury (113,927) -- (393,077)
Exercises of stock options 215,370 224,631 410,882
- -------------------------------------------------------------------------------------------------------------
NET CASH PROVIDED BY/(USED FOR) FINANCING ACTIVITIES (2,411,587) 6,020,733 (4,264,053)
- -------------------------------------------------------------------------------------------------------------
Effect of exchange rate changes on cash balances 5,712 (16,478) (24,949)
- -------------------------------------------------------------------------------------------------------------
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 1,198,870 (899,572) 751,591
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 1,744,734 2,644,306 1,892,715
- -------------------------------------------------------------------------------------------------------------
CASH AND CASH EQUIVALENTS, END OF YEAR $ 2,943,604 $ 1,744,734 $ 2,644,306
=============================================================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
Wyeth 31
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Summary of Significant Accounting Policies
PRINCIPLES OF CONSOLIDATION: The accompanying consolidated financial statements
include the accounts of Wyeth and subsidiaries (the Company). The financial
statements have been prepared in accordance with accounting principles generally
accepted in the United States, which require the use of judgments and estimates
made by management.
Effective January 1, 2000, the financial results of Immunex Corporation
(Immunex), which previously were consolidated, were deconsolidated and included
on an equity basis in the results of operations of the Company. During 2002,
Amgen Inc. (Amgen) completed its acquisition of Immunex. As a result, the
Company's investment in Immunex, which was previously accounted for on the
equity method, was exchanged for an investment in Amgen and was accounted for on
the cost method subsequent to July 15, 2002. See Note 2 for further description
of Immunex/Amgen common stock transactions.
Prior to 2000, certain of the Company's international affiliates reported
their results of operations on a one-month lag (year ended November 30), which
allowed more time to compile results. In December 2000, the one-month lag was
eliminated, primarily to reflect the results of these operations on a more
timely basis. As a result, December 2000 income from continuing operations for
these entities of $53.2 million was recorded directly to stockholders' equity.
DESCRIPTION OF BUSINESS: The Company is a U.S.-based multi-national
corporation engaged in the discovery, development, manufacture, distribution and
sale of a diversified line of products in two primary businesses:
Pharmaceuticals and Consumer Healthcare. Pharmaceuticals include branded human
ethical pharmaceuticals, biologicals, nutritionals, and animal biologicals and
pharmaceuticals. Principal products include women's health care products,
neuroscience therapies, cardiovascular products, nutritionals, gastroenterology
drugs, anti-infectives, vaccines, oncology therapies, musculoskeletal therapies,
hemophilia treatments and immunological products. Principal animal health
products include vaccines, pharmaceuticals, endectocides and growth implants.
Consumer Healthcare products include analgesics, cough/cold/allergy remedies,
nutritional supplements, herbal products, and hemorrhoidal, antacid, asthma and
other relief items sold over-the-counter. The Company sells its diversified line
of products to wholesalers, pharmacies, hospitals, physicians, retailers and
other health care institutions located in various markets in more than 140
countries throughout the world.
Wholesale distributors and large retail establishments account for a large
portion of the Company's consolidated net revenue and trade receivables,
especially in the United States. The Company's top three customers in the United
States accounted for 25% of the Company's consolidated net revenue in 2002, as
is typical in the pharmaceutical industry. In light of this concentration, the
Company continuously monitors the creditworthiness of its customers and has
established internal policies regarding customer credit limits.
The Company is not dependent on any one patent-protected product or line
of products for a substantial portion of its net revenue or results of
operations. However, Effexor, Premarin family products and Protonix, each of
which has sales in excess of $1,000.0 million, comprised approximately 14%, 13%
and 7%, respectively, of the Company's consolidated net revenue in 2002.
EQUITY METHOD OF ACCOUNTING: The Company accounts for its investments in
20%- to 50%-owned companies using the equity method. Accordingly, the Company's
share of the earnings of these companies is included in Other income, net. The
related equity method investment is included in Other assets including deferred
taxes. In 2001 and 2000, Immunex was the Company's only material equity method
investment. At December 31, 2002, the Company did not have any material equity
method investments. See Note 2 for discussion of Immunex-related transactions.
CASH EQUIVALENTS consist primarily of commercial paper, fixed-term
deposits and other short-term, highly liquid securities with original maturities
of three months or less and are stated at cost. The carrying value of cash
equivalents approximates fair value due to their short-term, highly liquid
nature.
MARKETABLE SECURITIES: The Company has marketable debt and equity
securities which are classified as either available-for-sale or
held-to-maturity, depending on management's investment intentions relating to
these securities. Available-for-sale securities are marked-to-market based on
quoted market values of the securities, with the unrealized gains and losses,
net of tax, reported as a component of Accumulated other comprehensive loss.
Realized gains and losses on sales of available-for-sale securities are computed
based upon initial cost adjusted for any other-than-temporary declines in fair
value. Investments categorized as held-to-maturity are carried at amortized cost
because the Company has both the intent and ability to hold these investments
until they mature. Impairment losses are charged to income for
other-than-temporary declines in fair value. Premiums and discounts are
amortized or accreted into earnings over the life of the related
available-for-sale or held-to-maturity security. Dividend and interest income is
recognized when earned. The Company owns no investments that are considered to
be trading securities.
INVENTORIES are valued at the lower of cost or market. Inventories valued
under the last-in, first-out (LIFO) method amounted to $360.3 million and $319.9
million at December 31, 2002 and 2001, respectively. The current value exceeded
the
32 Wyeth
LIFO value by $90.0 million and $59.5 million at December 31, 2002 and 2001,
respectively. The remaining inventories are valued primarily under the first-in,
first-out (FIFO) method.
Inventories at December 31 consisted of:
(In thousands) 2002 2001
- --------------------------------------------------------------------------------
Finished goods $ 736,360 $ 653,108
Work in progress 808,711 674,636
Materials and supplies 447,653 427,227
- --------------------------------------------------------------------------------
$1,992,724 $1,754,971
================================================================================
PROPERTY, PLANT AND EQUIPMENT IS CARRIED AT COST. Depreciation is provided
over the estimated useful lives of the related assets, principally on the
straight-line method, as follows:
Buildings 10 - 50 years
Machinery and equipment 3 - 20 years
Depreciable assets are reviewed for impairment whenever events or changes
in circumstances indicate that the carrying amount may not be recoverable based
on projected undiscounted cash flows associated with the affected assets. A loss
is recognized for the difference between the fair value and carrying amount of
the asset. Fair value is determined based on market quotes, if available, or is
based on valuation techniques.
GOODWILL AND OTHER INTANGIBLES: Goodwill is defined as the excess of cost
over the fair value of net assets acquired. On January 1, 2002, the Company
adopted Statement of Financial Accounting Standards (SFAS) No. 142, Goodwill and
Other Intangible Assets. With the adoption of SFAS No. 142, goodwill and other
intangibles with indefinite lives are no longer amortized but are subject to at
least an annual assessment for impairment by applying a fair value-based test.
Other intangibles with finite lives continue to be amortized. See Note 5 for
further detail relating to the Company's goodwill and other intangibles
balances.
DERIVATIVE FINANCIAL INSTRUMENTS: The Company currently manages its
exposure to certain market risks, including foreign exchange and interest rate
risks, through the use of derivative financial instruments and accounts for them
in accordance with SFAS Nos. 133, Accounting for Derivative Instruments and
Hedging Activities, and 138, Accounting for Certain Derivative Instruments and
Certain Hedging Activities.
On the date that the Company enters into a derivative contract, it
designates the derivative as: (1) a hedge of the fair value of a recognized
asset or liability (fair value hedge), (2) a hedge of a forecasted transaction
or the variability of cash flows that are to be received or paid in connection
with a recognized asset or liability (cash flow hedge), (3) a foreign currency
fair value or cash flow hedge (foreign currency hedge) or (4) a derivative
instrument that is not designated for hedge accounting treatment. For derivative
contracts that are designated and qualify as fair value hedges (including
foreign currency fair value hedges), the derivative instrument is
marked-to-market with gains and losses recognized in current period earnings to
offset the respective losses and gains recognized on the underlying exposure.
For derivative contracts that are designated and qualify as cash flow hedges
(including foreign currency cash flow hedges), the effective portion of gains
and losses on these contracts is reported as a component of accumulated other
comprehensive income (loss) and reclassified into earnings in the same period
the hedged transaction affects earnings. Any hedge ineffectiveness on cash flow
hedges is immediately recognized in earnings. The Company also enters into
derivative contracts that are not designated as hedging instruments. These
derivative contracts are recorded at fair value with the gain or loss recognized
in current period earnings. The Company does not hold any derivative instruments
for trading purposes. See Note 9 for further description of the Company's
specific programs to manage risk using derivative financial instruments.
CURRENCY TRANSLATION: The majority of the Company's international
operations are translated into U.S. dollars using current foreign currency
exchange rates with currency translation adjustments reflected in Accumulated
other comprehensive loss in stockholders' equity. Currency translation
adjustments related to international operations in highly inflationary economies
are included in the results of operations.
REVENUE RECOGNITION: Revenue from the sale of Company products is
recognized in Net revenue upon shipment to customers. Provisions for certain
rebates, product returns and discounts to customers are provided for as
deductions in determining Net revenue.
Revenue under co-promotion agreements from the sale of products developed
by other companies, such as the Company's arrangement with Amgen to co-promote
Enbrel and with King Pharmaceuticals, Inc. to co-promote Altace, is recorded as
alliance revenue, which is included in Net revenue. Such alliance revenue is
earned when the co-promoting company ships the product to a third party. Selling
and marketing expenses related to alliance revenue are included in Selling,
general and administrative expenses. Alliance revenue totaled $418.8 million,
$322.4 million and $188.3 million for 2002, 2001 and 2000, respectively.
SHIPPING AND HANDLING COSTS, which include transportation to customers,
transportation to distribution points, warehousing and handling costs, are
included in Selling, general and administrative expenses. The Company typically
does not charge customers for shipping and handling costs. Shipping and handling
costs were $227.5 million, $228.9 million and $212.5 million in 2002, 2001 and
2000, respectively.
REBATES AND SALES INCENTIVES, which are deducted to arrive at Net revenue,
are offered to customers based upon volume purchases, the attainment of market
share levels, government mandates, coupons and consumer discounts. These costs
are recognized at the later of a) the date at which the related revenue is
recorded or b) the date at which the incentives are offered. Rebates and sales
incentives accruals included in Accrued expenses at December 31, 2002 and 2001
were $722.5 million and $615.0 million, respectively.
STOCK-BASED COMPENSATION: The Company has five Stock Incentive Plans,
which are described more fully in Note 12. The Company accounts for those plans
using the intrinsic value method in accordance with APB Opinion No. 25,
Accounting for Stock Issued to Employees. No stock-based employee compensation
cost is reflected in net income, as all options granted under those plans had an
exercise price equal to the market value of the
Wyeth 33
underlying common stock on the date of grant. The following table illustrates
the effect on net income (loss) and earnings (loss) per share if the Company had
applied the fair value recognition provisions of SFAS No. 123, Accounting for
Stock-Based Compensation, to stock-based employee compensation:
(In thousands except per share amounts)
Years Ended December 31, 2002 2001 2000
- --------------------------------------------------------------------------------
Net income (loss), as reported $ 4,447,205 $ 2,285,294 $(2,370,687)
Deduct: total stock-based
employee compensation
expense determined under
fair value-based method for
all awards, net of tax 297,965 200,688 149,924
- --------------------------------------------------------------------------------
Pro forma net income (loss) $ 4,149,240 $ 2,084,606 $(2,520,611)
================================================================================
Earnings (loss) per share:
Basic - as reported $ 3.35 $ 1.74 $ (1.81)
================================================================================
Basic - pro forma $ 3.13 $ 1.58 $ (1.93)
================================================================================
Diluted - as reported $ 3.33 $ 1.72 $ (1.81)
================================================================================
Diluted - pro forma $ 3.11 $ 1.57 $ (1.93)
================================================================================
The fair value of issued stock options is estimated on the date of grant
using a variant of the Black-Scholes option pricing model incorporating the
following assumptions for stock options granted in 2002, 2001 and 2000,
respectively: expected volatility (the amount by which the stock price is
expected to fluctuate) of 33.7%, 32.1% and 31.2%; expected dividend yield of
1.9%, 1.6% and 1.6%; risk-free interest rate of 4.1%, 4.8% and 6.3%; and
expected life of five years. The weighted average fair value of stock options
granted during 2002, 2001 and 2000 was $16.12, $17.76 and $18.76 per option
share, respectively.
RESEARCH AND DEVELOPMENT EXPENSES are expensed as incurred. Upfront and
milestone payments made to third parties in connection with research and
development collaborations are expensed as incurred up to the point of
regulatory approval. Payments made to third parties subsequent to regulatory
approval are capitalized and amortized over the remaining useful life. Amounts
capitalized for such payments are included in Other intangibles, net of
accumulated amortization.
EARNINGS (LOSS) PER SHARE: The following table sets forth the computations
of basic earnings (loss) per share and diluted earnings (loss) per share:
(In thousands except per share amounts)
Years Ended December 31, 2002 2001 2000
- ----------------------------------------------------------------------------
Income (loss) from continuing
operations less preferred
dividends $ 4,447,167 $ 2,285,252 $ (901,086)
Loss from
discontinued operations -- -- (1,469,647)
- ----------------------------------------------------------------------------
Net income (loss) less
preferred dividends $ 4,447,167 $ 2,285,252 $(2,370,733)
Denominator:
Weighted average common
shares outstanding 1,325,577 1,317,102 1,306,474
- ----------------------------------------------------------------------------
Basic earnings (loss) per share
from continuing operations $ 3.35 $ 1.74 $ (0.69)
Basic loss per share from
discontinued operations -- -- (1.12)
- ----------------------------------------------------------------------------
Basic earnings (loss) per share $ 3.35 $ 1.74 $ (1.81)
============================================================================
Income (loss) from continuing
operations $ 4,447,205 $ 2,285,294 $ (901,040)
Loss from discontinued
operations -- -- (1,469,647)
- ----------------------------------------------------------------------------
Net income (loss) $ 4,447,205 $ 2,285,294 $(2,370,687)
Denominator:
Weighted average common
shares outstanding 1,325,577 1,317,102 1,306,474
Common stock equivalents
of outstanding stock
options and deferred
contingent common
stock awards(2) 8,550 13,707 --
- ----------------------------------------------------------------------------
Total shares(1)(2) 1,334,127 1,330,809 1,306,474
- ----------------------------------------------------------------------------
Diluted earnings (loss) per
share from continuing
operations(1)(2) $ 3.33 $ 1.72 $ (0.69)
Diluted loss per share from
discontinued operations(2) -- -- (1.12)
- ----------------------------------------------------------------------------
Diluted earnings (loss)
per share(1)(2) $ 3.33 $ 1.72 $ (1.81)
============================================================================
(1) At December 31, 2002 and 2001, the equivalent of 90,360,361 and 18,945,057
common shares, respectively, issuable under the Company's Stock Incentive
Plans, was excluded from the computation of diluted earnings per share
because their effect would have been antidilutive.
(2) The total weighted average common shares outstanding for diluted loss per
share for 2000 did not include common stock equivalents, as the effect
would have been antidilutive.
34 Wyeth
RECENTLY ISSUED ACCOUNTING STANDARDS: The Financial Accounting Standards
Board (FASB) recently issued Statement Nos. 145, 146 and 148 as well as
Interpretation Nos. 45 and 46, which require the following:
- SFAS No. 145, Rescission of FASB Statement Nos. 4, 44 and 64,
Amendment of FASB Statement No. 13, and Technical Corrections,
primarily relates to the reporting of gains and losses from the
extinguishment of debt. With the issuance of this Statement,
extinguishment of debt is not to be considered extraordinary if it
is part of an entity's risk management strategy. This Statement is
effective beginning January 1, 2003, and the Company does not
anticipate the adoption of this Statement to have any impact on its
financial position or results of operations.
- SFAS No. 146, Accounting for Costs Associated with Exit or Disposal
Activities, requires that a liability for a cost associated with an
exit or disposal activity, initiated after December 31, 2002, be
recognized and measured initially at fair value only when the
liability is incurred. This Statement nullifies Emerging Issues Task
Force (EITF) No. 94-3, Liability Recognition for Certain Employee
Termination Benefits and Other Costs to Exit an Activity (including
Certain Costs Incurred in a Restructuring), which permitted
recognition of a liability for an exit cost at the date of an
entity's commitment to an exit plan. The Company recorded the
restructuring component of its 2002 special charge in accordance
with EITF No. 94-3 and did not early adopt SFAS No. 146.
- SFAS No. 148, Accounting for Stock-Based Compensation - Transition
and Disclosure, Amendment of SFAS No. 123, provides alternative
methods of transition for a voluntary change to fair value-based
accounting for stock-based compensation. In addition, the Statement
amends the disclosure requirements of SFAS No. 123 to require
prominent disclosures in both interim and annual financial
statements about the method of accounting for stock-based employee
compensation and the effect the method used has on reported results.
The Company will continue to account for stock-based compensation
using the intrinsic value method but has adopted the disclosure
requirements prescribed by SFAS No. 148 as of December 31, 2002.
- FASB Interpretation No. 45 (FIN 45), Guarantor's Accounting and
Disclosure Requirements for Guarantees, Including Indirect
Guarantees of Indebtedness of Others, Interpretation of FASB
Statement Nos. 5, 57, and 107 and Rescission of FIN 34, clarifies
the requirements of SFAS No. 5, Accounting for Contingencies,
relating to the guarantor's accounting for, and disclosure of, the
issuance of certain types of guarantees. FIN 45 requires, that upon
issuance of a guarantee, the entity must recognize a liability for
the fair value of the obligation it assumes under the guarantee. The
disclosure provisions of the Interpretation are effective for
financial statements of interim or annual periods that end after
December 15, 2002, while the initial recognition and measurement
provisions are effective on a prospective basis for guarantees that
are issued or modified after December 31, 2002. The Company does not
anticipate that the adoption of this Interpretation will have a
material impact on its financial position or results of operations.
- FIN 46, Consolidation of Variable Interest Entities, an
Interpretation of ARB No. 51, provides guidance on: (1) the
identification of entities for which control is achieved through
means other than through voting rights and (2) how to determine when
and which business enterprise should consolidate such entities. In
addition, FIN 46 requires that any enterprises with a significant
variable interest in these types of entities make additional
disclosures in all financial statements initially issued after
January 31, 2003. The Company does not anticipate the adoption of
this Interpretation will have any impact on its financial position
or results of operations.
RECLASSIFICATIONS: Certain reclassifications have been made to the December 31,
2001 and 2000 consolidated financial statements to conform with the December 31,
2002 presentation.
2. Divestitures and Discontinued Operations
IMMUNEX/AMGEN TRANSACTIONS
Acquisition of Immunex by Amgen and Related Sales of Amgen Common Stock
During 2002, the Company recorded gains totaling $4,082.2 million ($2,628.1
million after-tax or $1.97 per share-diluted) relating to the acquisition of
Immunex by Amgen and the subsequent sales of Amgen common stock.
Prior to July 15, 2002, the Company was the beneficial owner of
223,378,088 shares of Immunex common stock. On July 15, 2002, Amgen completed
its acquisition of Immunex. Under the terms of the acquisition agreement, each
share of Immunex common stock was exchanged for 0.44 shares of Amgen common
stock and $4.50 in cash. Accordingly, the Company received 98,286,358 shares of
Amgen common stock (representing approximately 7.7% of Amgen's outstanding
common stock) and $1,005.2 million in cash in exchange for all of its shares of
Immunex common stock.
Pursuant to the terms of the acquisition, the Company and Amgen had agreed
to certain standstill, voting, lock-up and sales volume limitation provisions
with respect to the Amgen common stock received by the Company. These provisions
prohibited the Company, without the consent of Amgen, from disposing of greater
than an aggregate of 20,000,000 shares of Amgen common stock in any calendar
quarter, with certain exceptions, including the right to request a limited
number of underwritten offerings.
The pre-tax gains of $4,082.2 million recorded in 2002 consisted of
$2,627.6 million relating to the initial acquisition of Immunex by Amgen and
$1,454.6 million relating to the subsequent sales of Amgen common stock and were
determined as follows:
1. As of July 15, 2002, the Company had valued its shares of Amgen
common stock at $2,500.1 million based on the quoted market price in
effect as of July 15, 2002 reduced
Wyeth 35
by an overall discount of approximately 18%. The discount rate was
based on valuations provided by independent valuation consultants in
light of the various restrictions on the stock's marketability
referred to above. The book value of the Company's Immunex
investment was $867.7 million at July 15, 2002. A gain of $2,627.6
million ($1,684.7 million after-tax or $1.26 per share-diluted) was
recorded on the exchange during the 2002 third quarter and was
calculated as follows:
(In thousands)
- --------------------------------------------------------------------------------
Value received:
Cash $1,005,201
Amgen common stock 2,500,100
- --------------------------------------------------------------------------------
3,505,301
Less:
Equity investment in Immunex 867,701
Transaction costs 10,000
- --------------------------------------------------------------------------------
877,701
- --------------------------------------------------------------------------------
Gain before federal taxes 2,627,600
Provision for federal taxes 942,877
- --------------------------------------------------------------------------------
Net gain $1,684,723
================================================================================
2. Following the expiration of the 90-day lock-up period, the Company
commenced selling its shares of Amgen common stock and, in the
fourth quarter, obtained the consent of Amgen to exceed the sale
limitation for such quarter. As of December 31, 2002, the Company
sold 67,050,400 shares of Amgen common stock generating net proceeds
of $3,250.8 million. The net proceeds of $3,250.8 million generated
a pre-tax gain of $1,454.6 million ($943.4 million after-tax or
$0.71 per share-diluted). The gain was determined by comparing the
basis of the shares sold of $1,782.7 million with the net proceeds
received reduced by certain related expenses.
The remaining 31,235,958 shares of Amgen common stock held by the Company
at December 31, 2002 had a fair value of $1,509.9 million, which included a
mark-to-market gain of $515.1 million, net of tax, recorded as a component of
Accumulated other comprehensive loss. The Company completed the sales of its
remaining Amgen shares by January 21, 2003. These remaining shares netted
proceeds of $1,579.9 million and resulted in an after-tax gain of $558.7
million, which will be recorded in the 2003 first quarter.
The Company and Amgen continue to co-promote Enbrel in the United States
and Canada with the Company having exclusive international rights to Enbrel. The
financial aspects of the existing licensing and marketing rights to Enbrel
remain unchanged.
2000 Transactions in Immunex Common Stock
In October 2000, the Company increased its ownership in Immunex (subsequently
acquired by Amgen) from approximately 53% to approximately 55% by converting a
$450.0 million convertible subordinated note into 15,544,041 newly issued shares
of Immunex common stock. In November 2000, through a public equity offering, the
Company sold 60.5 million shares of Immunex common stock, and Immunex sold 20
million shares of newly issued Immunex common stock. Proceeds to the Company
were approximately $2,404.9 million resulting in a gain on the sale of $2,061.2
million ($1,414.9 million after-tax or $1.08 per share-diluted). Included in the
gain on the sale was a noncash pre-tax gain of $303.2 million ($200.2 million
after-tax), representing the Company's increase in its proportionate share of
the net book value of Immunex from Immunex's issuance of 20 million shares of
its common stock at a price above the net book value per share owned by the
Company. The Company used the net proceeds from the sale of its Immunex common
stock to reduce outstanding commercial paper and for other general corporate
purposes.
The public equity offering reduced the Company's ownership in Immunex from
approximately 55% to approximately 41%, which represented the ownership at
December 31, 2001 and 2000. As a result of the reduction in ownership below 50%,
the Company included the financial results of Immunex on an equity basis
retroactive to January 1, 2000.
Sale of Rhode Island Facility
During the first quarter of 2002, the Company completed the sale of a
manufacturing plant located in West Greenwich, Rhode Island, to Immunex
(subsequently acquired by Amgen) for $487.8 million. The Company received $189.2
million of these proceeds in 2001 and the remaining $298.6 million during the
2002 first quarter. The Company did not recognize a gain on this transaction
because the facility was sold at net book value. In December 2002, the U.S. Food
and Drug Administration (FDA) approved the Rhode Island facility, which will be
dedicated to expanding the production capacity of Enbrel.
SALE OF LEDERLE GENERIC INJECTABLES PRODUCT LINE
In December 2002, the Company sold to Baxter Healthcare Corporation certain
assets related to the Company's generic human injectables product line for
$305.0 million in cash. This transaction resulted in a gain of $172.9 million
($108.9 million after-tax or $0.08 per share-diluted), which was recorded in
Other income, net.
DISCONTINUED OPERATIONS - CYANAMID AGRICULTURAL PRODUCTS
On March 20, 2000, the Company signed a definitive agreement with BASF
Aktiengesellschaft (BASF) to sell the Cyanamid Agricultural Products business,
which manufactures, distributes and sells crop protection and pest control
products worldwide. On June 30, 2000, the sale was completed, and BASF paid the
Company $3,800.0 million in cash and assumed certain debt. The Company recorded
an after-tax loss on the sale of this business and reflected this business as a
discontinued operation in the 2000 first quarter. The loss on the sale included
closing costs from the transaction and reflected operating income of the
discontinued business from April 1, 2000 through June 30, 2000 (the disposal
date). The loss on the sale was determined based on the difference in the book
value of the net assets sold compared with the price received for these net
assets. The sale of the Cyanamid Agricultural Products business produced a gain
for tax purposes and a loss for book purposes, as the Company did not get a
step-up in cost basis for tax purposes. This divergence, primarily caused by
goodwill, was included in the basis for book purposes but was not included in
the basis for tax purposes. The lower tax basis created a taxable gain that
36 Wyeth
required a tax provision of approximately $855.2 million. This tax provision was
combined with the pre-tax book loss of approximately $717.8 million for a total
after-tax loss on the sale of the business of $1,573.0 million or $1.20 per
share-diluted. Operating results of discontinued operations as of December 31,
2000 were as follows:
STATEMENT OF
(In thousands except per share amounts) OPERATIONS
- --------------------------------------------------------------------------------
Net revenue $ 546,790
- --------------------------------------------------------------------------------
Income before federal and foreign taxes 160,635
Provision for federal and foreign taxes 57,289
- --------------------------------------------------------------------------------
Income from operations of discontinued
agricultural products business 103,346
Loss on disposal of agricultural products
business (net of federal and foreign
taxes of $855,248) (1,572,993)
- --------------------------------------------------------------------------------
Loss from discontinued operations $(1,469,647)
================================================================================
Diluted loss per share from
discontinued operations $ (1.12)
================================================================================
3. Special Charges, Goodwill Impairment and Termination Fee
SPECIAL CHARGES
Restructuring Charge and Related Asset Impairments
In December 2002, the Company recorded a special charge for restructuring and
related asset impairments of $340.8 million ($233.5 million after-tax or $0.18
per share-diluted). The Company recorded its asset impairments in accordance
with SFAS No. 144, Accounting for the Impairment and Disposal of Long-Lived
Assets, and its restructuring charges, including personnel and other costs, in
accordance with EITF No. 94-3. The Company has not early adopted SFAS No. 146.
Any charges associated with future restructuring programs will be recorded in
accordance with SFAS No. 146. This will spread the recognition of the
restructuring expenses over a number of accounting periods as compared with EITF
No. 94-3.
The restructuring charge and related asset impairments were recorded to
recognize the costs of closing certain manufacturing facilities and two research
facilities, as well as the elimination of certain positions at the Company's
facilities. The related asset impairments of $68.7 million were determined by
comparing the carrying value of the long-lived assets to the discounted cash
flows that are expected to be generated by these assets. The fixed assets that
have remained in use have been categorized as held and used. The depreciation
has been adjusted to reflect the reduced carrying values of the facilities,
which will be recognized over the closure period.
The closing of the manufacturing and research facilities and reduction of
sales and administrative-related positions cover approximately 3,150 employees
worldwide. The reductions in workforce are permanent and affected all of the
Company's operating segments, including Corporate. Approximately 1,200 of these
positions are located at the manufacturing and research facilities that will be
closed. Of the 3,150 positions to be eliminated, 2,230 were located in North
America, 370 in Europe, 300 in Latin America and 250 in Asia-Pacific. At
December 31, 2002, approximately 2,250 positions had been eliminated. A majority
of the personnel costs associated with these reductions will be paid in 2003.
Other closure/exit costs are a direct result of the restructuring plan.
The majority of the other closure/exit costs are anticipated to be paid after
the facilities cease production and prior to disposition. These costs include
non-cancelable operating leases, security, utilities, maintenance, property
taxes and other related costs that will be paid during the disposal period. The
Company estimated the cost of exiting and terminating the facility leases based
on the contractual terms of the agreements and real estate market conditions.
Amounts related to the lease expense will be paid over the remaining lease terms
through 2012.
Activity in the reserves from the 2002 special charge was as follows:
PERSONNEL FIXED ASSET OTHER CLOSURE/
(In thousands) COSTS IMPAIRMENTS EXIT COSTS TOTAL
- -------------------------------------------------------------------------------------------------------------------
2002 special charge reserves at inception $ 194,600 $ 68,700 $ 77,500 $ 340,800
Cash expenditures (30,900) -- (4,500) (35,400)
Impairments of fixed assets -- (68,700) -- (68,700)
- -------------------------------------------------------------------------------------------------------------------
2002 special charge reserves at December 31, 2002 $ 163,700 $ -- $ 73,000 $ 236,700
===================================================================================================================
Product Discontinuations
During the 2000 fourth quarter, the Company recorded a special charge of $267.0
million ($173.0 million after-tax or $0.13 per share-diluted) related to the
discontinuation of certain products manufactured at the Company's Marietta,
Pennsylvania, and Pearl River, New York, facilities. Approximately $227.1
million related to noncash costs for fixed asset impairments and inventory
write-offs, with the remainder of the charge covering severance obligations,
idle plant costs and contract termination costs. During 2002 and 2001,
approximately $3.6 million and $7.8 million, respectively, of these costs were
paid, leaving an accrual of $28.5 million at December 31, 2002. The timing of
the remaining costs to be incurred has been delayed as the Company has continued
to produce certain products in response to a
Wyeth 37
potential market shortage for these products and the related medical necessity.
As a result, the majority of the remaining costs will be expended in 2003.
Voluntary Market Withdrawals
In November 2000, the FDA requested that the pharmaceutical industry voluntarily
stop producing and distributing products containing phenylpropanolamine (PPA).
The Company immediately ceased global production and shipments of any products
containing PPA and voluntarily withdrew any such products from customer
warehouses and retail store shelves. As a result, the Company recorded a special
charge of $80.0 million ($52.0 million after-tax or $0.04 per share-diluted) to
provide primarily for product returns and the write-off of inventory. The
Company already had reformulated a majority of the products involved in the
voluntary market withdrawal and began shipping those products in the United
States at the end of November 2000. At December 31, 2001, all amounts provided
for the PPA voluntary market withdrawal had been utilized.
GOODWILL IMPAIRMENT
Based on projected profitability and future cash flows associated with the solid
dose generic pharmaceuticals and the Solgar consumer healthcare product line, it
was determined that goodwill related to these product lines, at December 31,
2000, was impaired. As a result, the Company recorded a charge of $401.0 million
($341.0 million after-tax or $0.26 per share-diluted) in 2000 to write down the
carrying value of goodwill, to fair value, based upon discounted future cash
flows.
TERMINATION FEE
On November 3, 1999, the Company and Warner-Lambert Company entered into an
agreement to combine the two companies in a merger-of-equals transaction. On
February 6, 2000, the merger agreement was terminated. The Company recorded
income of $1,709.4 million ($1,111.1 million after-tax or $0.85 per
share-diluted) in 2000 resulting from the receipt of a $1,800.0 million
termination fee provided for under the merger agreement offset, in part, by
certain related expenses.
4. Marketable Securities
The cost, gross unrealized gains (losses) and fair value of available-for-sale
and held-to-maturity securities by major security type at December 31, 2002 and
2001 were as follows:
GROSS GROSS
(In thousands) UNREALIZED UNREALIZED FAIR
At December 31, 2002 COST GAINS (LOSSES) VALUE
- ---------------------------------------------------------------------------------------------------
Available-for-sale:
U.S. Treasury securities $ 105,583 $ 615 $ (15) $ 106,183
Commercial paper 57,397 -- -- 57,397
Certificates of deposit 29,218 77 -- 29,295
Corporate debt securities 214,127 1,202 (388) 214,941
Other debt securities 9,702 150 -- 9,852
Institutional fixed income fund 510,574 16,312 -- 526,886
- ---------------------------------------------------------------------------------------------------
Total available-for-sale 926,601 18,356 (403) 944,554
- ---------------------------------------------------------------------------------------------------
Held-to-maturity:
Time/term deposits 30,002 -- -- 30,002
U.S. Treasury securities 1,996 -- -- 1,996
Commercial paper 10,473 -- -- 10,473
Certificates of deposit 15,251 -- -- 15,251
Other debt securities 999 -- -- 999
- ---------------------------------------------------------------------------------------------------
Total held-to-maturity 58,721 -- -- 58,721
- ---------------------------------------------------------------------------------------------------
$ 985,322 $ 18,356 $ (403) $ 1,003,275
===================================================================================================
GROSS GROSS
(In thousands) UNREALIZED UNREALIZED FAIR
At December 31, 2001 COST GAINS (LOSSES) VALUE
- ---------------------------------------------------------------------------------------------------
Available-for-sale:
Time/term deposits $ 900,900 $ -- $ -- $ 900,900
Commercial paper 363,665 -- -- 363,665
Certificates of deposit 7,469 -- -- 7,469
Government securities 7,949 -- -- 7,949
Other debt securities 2,005 -- -- 2,005
- ---------------------------------------------------------------------------------------------------
Total available-for-sale $ 1,281,988 $ -- $ -- $ 1,281,988
===================================================================================================
38 Wyeth
The contractual maturities of debt securities classified as available-for-sale
and held-to-maturity as of December 31, 2002 were as follows:
Fair
(In thousands) Cost Value
- --------------------------------------------------------------------------------
Available-for-sale:
Due within one year $204,238 $204,207
Due after one year through five years 198,197 199,865
Due after five years through 10 years -- --
Due after 10 years 13,592 13,596
- --------------------------------------------------------------------------------
$416,027 $417,668
================================================================================
Held-to-maturity:
Due within one year $ 58,721 $ 58,721
Due after one year through five years -- --
Due after five years through 10 years -- --
Due after 10 years -- --
- --------------------------------------------------------------------------------
$ 58,721 $ 58,721
================================================================================
5. Goodwill and Other Intangibles
In accordance with SFAS No. 142, goodwill is required to be tested for
impairment at the reporting unit level utilizing a two-step methodology. The
initial step requires the Company to determine the fair value of each reporting
unit and compare it with the carrying value, including goodwill, of such unit.
If the fair value exceeds the carrying value, no impairment loss would be
recognized. However, if the carrying value of this unit exceeds its fair value,
the goodwill of the unit may be impaired. The amount, if any, of the impairment
then would be measured in the second step.
Goodwill in each reporting unit was tested for impairment as of the
beginning of the fiscal year in which SFAS No. 142 was initially adopted
(transitional impairment test). Thereafter, it is required that goodwill must be
tested for impairment at least on an annual basis (annual impairment test). The
Company completed step one of the transitional impairment test during the second
quarter of 2002 and its annual impairment test in the fourth quarter and
determined there was no impairment of the recorded goodwill for any of the
reporting units.
The Company's other intangibles, which all have finite lives, are being
amortized over their estimated useful lives ranging from three to 10 years.
The following table presents the transitional disclosures for income
(loss) from continuing operations and basic and diluted earnings (loss) per
share from continuing operations for the years ended December 31, 2002, 2001 and
2000, respectively, to reflect the adoption of SFAS No. 142 as of January 1,
2002. Such disclosures add back goodwill amortization to the 2001 and 2000
results to be comparable with the 2002 results, which do not include goodwill
amortization in accordance with the adoption of SFAS No. 142:
(In thousands except per share amounts)
2002 2001 2000
- --------------------------------------------------------------------------------
As-reported income (loss) from
continuing operations $ 4,447,205 $ 2,285,294 $ (901,040)
Add back: goodwill amortization -- 153,926 172,206
- --------------------------------------------------------------------------------
Adjusted income (loss) from
continuing operations $ 4,447,205 $ 2,439,220 $ (728,834)
================================================================================
Basic earnings (loss) per share from continuing operations:
As-reported $ 3.35 $ 1.74 $ (0.69)
Add back: goodwill amortization -- 0.12 0.13
- --------------------------------------------------------------------------------
Adjusted $ 3.35 $ 1.86 $ (0.56)
================================================================================
Diluted earnings (loss) per share from continuing operations:
As-reported $ 3.33 $ 1.72 $ (0.69)
Add back: goodwill amortization -- 0.12 0.13
- --------------------------------------------------------------------------------
Adjusted $ 3.33 $ 1.84 $ (0.56)
================================================================================
The changes in the carrying amount of goodwill by segment for the year ended
December 31, 2002 were as follows:
PHARMA- CONSUMER
(In thousands) CEUTICALS HEALTHCARE TOTAL
- --------------------------------------------------------------------------------
Balance at January 1, 2002 $ 3,136,543 $ 589,004 $ 3,725,547
Goodwill write-off* (10,035) -- (10,035)
Currency translation adjustments 28,895 1,342 30,237
- --------------------------------------------------------------------------------
Balance as of December 31, 2002 $ 3,155,403 $ 590,346 $ 3,745,749
================================================================================
* Write-off relates primarily to allocation of goodwill to the Company's
generic human injectables product line, which was sold in the 2002 fourth
quarter (see Note 2).
6. Debt and Financing Arrangements
The Company's debt at December 31 consisted of:
(In thousands) 2002 2001
- --------------------------------------------------------------------------------
Commercial paper $3,787,145 $4,817,205
Notes payable:
6.50% Notes due 2002 -- 250,000
5.875% Notes due 2004 500,000 500,000
7.90% Notes due 2005 1,000,000 1,000,000
6.25% Notes due 2006 1,000,000 1,000,000
6.70% Notes due 2011 1,500,000 1,500,000
7.25% debentures due 2023 250,000 250,000
Pollution control and industrial revenue bonds:
2.1%-5.8% due 2006-2018 74,250 83,950
Other debt:
0.7%-17.0% due 2003-2009 38,760 40,674
Fair value of debt attributable to interest
rate swaps 200,780 12,802
- --------------------------------------------------------------------------------
8,350,935 9,454,631
Less current portion 804,894 2,097,354
- --------------------------------------------------------------------------------
$7,546,041 $7,357,277
================================================================================
Wyeth 39
The fair value of the Company's outstanding debt was $8,471.8 million and
$9,607.7 million at December 31, 2002 and 2001, respectively. The fair value of
the Company's outstanding debt was estimated based on market prices.
The weighted average interest rate on the commercial paper outstanding at
December 31, 2002 and 2001 was 1.87% and 2.09%, respectively. The commercial
paper had original maturities that did not exceed 270 days and a weighted
average remaining maturity of 25 days and 37 days at December 31, 2002 and 2001,
respectively.
REVOLVING CREDIT FACILITIES
In March 2001, the Company obtained a $3,000.0 million, 364-day credit facility
(which supported borrowings under the commercial paper program). In March 2002,
the Company renewed this $3,000.0 million credit facility for an additional
364-day term. Any borrowings under the $3,000.0 million, 364-day credit facility
that are outstanding upon its termination in March 2003 are extendible by the
Company for an additional year. The portion of commercial paper outstanding at
December 31, 2002 supported by the $3,000.0 million, 364-day credit facility was
classified as Long-term debt since the Company intends, and has the ability, to
refinance these obligations through the issuance of additional commercial paper
or through the use of its $3,000.0 million credit facility as described above.
The credit facility contains substantially identical financial and other
covenants, representations, warranties, conditions and default provisions as the
March 2001 credit facility.
In March 2002, the Company reduced its $2,000.0 million credit facility to
$1,000.0 million, which terminated on July 31, 2002. Subsequent to the
termination, in August 2002, the Company obtained a new 364-day $2,000.0 million
credit facility which supported borrowings under the commercial paper program.
As a result of the proceeds received from the sales of the Company's Amgen
common stock holdings, the committed amount available under the facility was
reduced to zero on December 30, 2002, and the facility was terminated.
The proceeds from the credit facilities may be used to support commercial
paper and the Company's general corporate and working capital requirements,
including payments related to the Redux and Pondimin diet drug litigation. At
December 31, 2002 and 2001, there were no borrowings outstanding under the
facilities.
NOTES
On March 30, 2001, the Company issued $3,000.0 million of Senior Notes (the
Notes). These Notes consisted of three tranches, which pay interest semiannually
on March 15 and September 15, in a transaction exempt from registration under
the Securities Act of 1933, as amended (the Securities Act), pursuant to Rule
144A, as follows:
- $500.0 million 5.875% Notes due March 15, 2004
- $1,000.0 million 6.25% Notes due March 15, 2006
- $1,500.0 million 6.70% Notes due March 15, 2011
As of June 15, 2001, pursuant to an exchange offer made by the Company,
substantially all the Notes had been exchanged for new notes which have almost
identical terms and which have been registered under the Securities Act.
The interest rate payable on each series of Notes is subject to an
increase of 0.25 percentage points per level of downgrade in the Company's
credit rating by Moody's or S&P. However, the total adjustment to the interest
rate for the series of Notes cannot exceed two percentage points. There is no
adjustment to the interest rate payable on each series of Notes for the first
single-level downgrade in the Company's credit rating by S&P. The Company would
incur a total of approximately $7.5 million of additional annual interest
expense for every 0.25 percentage point increase in the interest rate. If
Moody's or S&P subsequently were to increase the Company's credit rating, the
interest rate payable on each series of Notes is subject to a decrease of 0.25
percentage points for each level of credit rating increase. The interest rate
payable for the series of Notes cannot be reduced below the original coupon rate
of each series of Notes. In the case of the $1,500.0 million 6.70% Notes, the
interest rate in effect on March 15, 2006 for such Notes will, thereafter,
become the effective interest rate until maturity on March 15, 2011.
The Company entered into two $750.0 million notional amount interest rate
swaps relating to the $1,500.0 million 6.70% Notes under which the Company
effectively converted the fixed rate of interest on these Notes to a floating
rate, which is based on LIBOR. See Note 9 for further discussion of the interest
rate swaps.
In addition to the $3,000.0 million of Notes described above, the Company
has outstanding the following non-callable, unsecured and unsubordinated debt
instruments:
- $1,000.0 million 7.90% Notes due February 2005 with interest
payments due on February 15 and August 15
- $250.0 million 7.25% debentures due March 2023 with interest
payments due on March 1 and September 1
The aggregate maturities of debt during the next five years and thereafter
at December 31, 2002 are as follows:
(In thousands)
- --------------------------------------------------------------------------------
2003 $ 804,894
2004 506,476
2005 1,017,988
2006 1,012,487
2007 387
Thereafter 2,008,703
- --------------------------------------------------------------------------------
5,350,935
Commercial paper classified as Long-term debt 3,000,000
- --------------------------------------------------------------------------------
Total debt $8,350,935
================================================================================
Interest payments in connection with the Company's debt obligations for
the years ended December 31, 2002, 2001 and 2000 amounted to $375.8 million,
$331.7 million and $343.0 million, respectively.
Interest expense, net included interest income of $92.1 million, $154.8
million and $181.3 million in 2002, 2001 and 2000, respectively. Interest
capitalized in connection with capital projects was $88.0 million, $94.3 million
and $43.3 million in 2002, 2001 and 2000, respectively.
40 Wyeth
7. Other Noncurrent Liabilities
Other noncurrent liabilities includes reserves for the Redux and Pondimin
litigation (see Note 14), reserves relating to income taxes, environmental
matters, product liability and other litigation, as well as restructuring,
pension and other employee benefit liabilities, and minority interests.
The Company has responsibility for environmental, safety and cleanup
obligations under various local, state and federal laws, including the
Comprehensive Environmental Response, Compensation and Liability Act, commonly
known as Superfund. It is the Company's policy to accrue for environmental
cleanup costs if it is probable that a liability has been incurred and an amount
is reasonably estimable. In many cases, future environmental-related
expenditures cannot be quantified with a reasonable degree of accuracy.
Environmental expenditures that relate to an existing condition caused by past
operations that do not contribute to current or future results of operations are
expensed. As investigations and cleanups proceed, environmental-related
liabilities are reviewed and adjusted as additional information becomes
available. The aggregate environmental-related accruals were $379.7 million and
$364.2 million at December 31, 2002 and 2001, respectively.
Environmental-related accruals have been recorded without giving effect to any
possible future insurance proceeds or the timing of payments. See Note 14 for
discussion of contingencies.
In 2000, the Company introduced a new incentive program to employees, the
Performance Incentive Award Program (PIA), which provides financial awards to
employees based on the Company's operating results and the individual employee's
performance. Substantially all U.S. and Puerto Rico exempt employees, who are
not subject to other incentive programs, and key international employees are
eligible to receive cash awards under PIA. The value of PIA awards for 2002,
2001 and 2000 was $39.6 million, $117.3 million and $94.7 million, respectively.
Through 1998, the Company provided incentive awards under the Management
Incentive Plan (MIP), which provided for cash and deferred contingent common
stock awards to key employees. Deferred contingent common stock awards plus
accrued dividends, related to the MIP program, totaling 798,304 and 875,206
shares were outstanding at December 31, 2002 and 2001, respectively.
8. Pensions and Other Postretirement Benefits
PENSIONS: The Company sponsors various retirement plans for most full-time
employees. These defined benefit and defined contribution plans cover all U.S.
and certain international locations. Total pension expense from continuing
operations for both defined benefit and defined contribution plans for 2002,
2001 and 2000 was $208.5 million, $141.9 million and $107.7 million,
respectively. Pension expense from continuing operations for defined
contribution plans for 2002, 2001 and 2000 totaled $71.1 million, $67.0 million
and $62.9 million, respectively.
Pension plan benefits for defined benefit plans are based primarily on
participants' compensation and years of credited service. Pension plan assets to
fund the Company's obligations are invested in accordance with certain asset
allocation criteria and investment guidelines established by the Company.
Investment responsibility for these assets is assigned to outside investment
managers, and employees do not have the ability to direct these assets.
Generally, contributions to defined contribution plans are based on a
percentage of the employee's compensation. The Company's 401(k) savings plans
have been established for substantially all U.S. employees. Certain employees
are eligible to enroll in the plan on their hire date and can contribute between
1% and 16% of their annual pay. The Company provides a matching contribution to
eligible participants of 50% on the first 6% of annual pay contributed to the
plan, or a maximum of 3% of annual pay. Employees can direct their contributions
and the Company's matching contributions into any of the funds offered. These
funds provide participants with a cross section of investing options, including
the Company's common stock. All contributions to the Company's common stock,
whether by employee or employer, can be transferred to other fund choices daily.
OTHER POSTRETIREMENT BENEFITS: The Company provides postretirement health
care and life insurance benefits for retired employees of most U.S. locations
and Canada. Most full-time employees become eligible for these benefits after
attaining specified age and service requirements.
The change in projected benefit obligation, change in plan assets,
reconciliation of funded status and amounts recognized in the consolidated
balance sheets for the Company's defined benefit plans (principally U.S. plans)
for 2002 and 2001 were as follows:
PENSIONS OTHER POSTRETIREMENT BENEFITS
--------------------------- -----------------------------
CHANGE IN PROJECTED BENEFIT OBLIGATION (In thousands) 2002 2001 2002 2001
- --------------------------------------------------------------------------------------------------------------------
Projected benefit obligation at January 1 $ 3,316,032 $ 3,210,575 $ 1,270,085 $ 1,020,330
Service cost 95,695 78,634 31,764 24,179
Interest cost 233,169 226,786 87,681 76,966
Amendments and other adjustments 95,537 9,796 (38,331) --
Net actuarial loss 418,212 104,938 170,301 227,758
Benefits paid (302,082) (284,603) (88,707) (78,516)
Currency translation adjustment 38,206 (30,094) 333 (632)
- --------------------------------------------------------------------------------------------------------------------
Projected benefit obligation at December 31 $ 3,894,769 $ 3,316,032 $ 1,433,126 $ 1,270,085
====================================================================================================================
Wyeth 41
PENSIONS OTHER POSTRETIREMENT BENEFITS
--------------------------- -----------------------------
CHANGE IN PLAN ASSETS (In thousands) 2002 2001 2002 2001
- --------------------------------------------------------------------------------------------------------------------
Fair value of plan assets at January 1 $ 2,738,622 $ 2,816,016 $ -- $ --
Actual return on plan assets (215,402) (213,908) -- --
Amendments and other adjustments 67,175 6,754 -- --
Company contributions 909,602 429,710 88,707 78,516
Benefits paid (302,082) (284,603) (88,707) (78,516)
Currency translation adjustment 17,113 (15,347) -- --
- --------------------------------------------------------------------------------------------------------------------
Fair value of plan assets at December 31 $ 3,215,028 $ 2,738,622 $ -- $ --
====================================================================================================================
PENSIONS OTHER POSTRETIREMENT BENEFITS
--------------------------- -----------------------------
RECONCILIATION OF FUNDED STATUS (In thousands) 2002 2001 2002 2001
- --------------------------------------------------------------------------------------------------------------------
Funded status $ 679,741 $ 577,410 $ 1,433,126 $ 1,270,085
Unrecognized net actuarial loss (1,459,416) (603,051) (406,684) (243,292)
Unrecognized prior service cost (55,283) (57,193) 23,639 (16,695)
Unrecognized net transition obligation (4,717) (5,301) -- --
- --------------------------------------------------------------------------------------------------------------------
Net amount recognized $ (839,675) $ (88,135) $ 1,050,081 $ 1,010,098
====================================================================================================================
PENSIONS
AMOUNT RECOGNIZED IN THE ----------------------------
CONSOLIDATED BALANCE SHEETS (In thousands) 2002 2001
- --------------------------------------------------------------------------------------------------------------------
Prepaid benefit cost $(1,084,072) $ (212,967)
Accrued benefit liability 335,421 124,832
Intangible asset (19,943) --
Accumulated other comprehensive income (71,081) --
- --------------------------------------------------------------------------------------------------------------------
Net amount recognized $ (839,675) $ (88,135)
====================================================================================================================
At December 31, 2002 and 2001, the accumulated benefit obligations (ABO),
which represent the obligations for benefits earned in the defined benefit plans
before considering plan assets, were $3,449.3 million and $2,971.8 million,
respectively. The ABO exceeded the plan assets by $234.3 million and $233.2
million at December 31, 2002 and 2001, respectively. This difference is
primarily attributable to unfunded executive retirement plans and certain
international plans.
In December 2002 and 2001, the Company made contributions to the U.S.
defined benefit pension plans of $875.0 million and $400.0 million,
respectively, due primarily to the decrease in the plan assets and, as a result,
the anticipation of future statutory funding requirements. The contributions
made during the last two years fully funded the primary U.S. defined benefit
pension plan. The decline in the global equity markets that occurred during the
past three years contributed significantly to the decrease in the plan assets.
The impact of the negative market returns caused most of the increase in the
unrecognized net actuarial loss since most of the difference between the
expected return and actual return on plan assets is deferred.
The net actuarial loss for other postretirement benefits of $170.3 million
in 2002 resulted primarily from a change in the assumption for future increases
in per capita cost of health care benefits and other changes in actuarial
assumptions.
There were no plan assets for the Company's other postretirement benefit
plans at December 31, 2002 and 2001 as postretirement benefits are funded by the
Company when claims are paid. The current portion of the accrued benefit
liability for other postretirement benefits was $85.0 million at December 31,
2002 and 2001.
Assumptions used in developing the projected benefit obligations at
December 31 were as follows (the expected return on plan assets is used in the
determination of the net periodic benefit cost in the following year):
PENSIONS OTHER POSTRETIREMENT BENEFITS
WEIGHTED AVERAGE ASSUMPTIONS ----------------------------------- ---------------------------------
AT DECEMBER 31, 2002 2001 2000 2002 2001 2000
- -------------------------------------------------------------------------------------------------------------------------------
Discount rate 6.75% 7.25% 7.5% 6.75% 7.25% 7.5%
Rate of compensation Increase 4.0% 4.0% 4.0% -- -- --
Expected return on plan assets 9.0% 9.25% 9.5% -- -- --
Increases in per capita cost of health care benefits
that gradually decrease and are held constant
after four years -- -- -- 9.5%-5.0% 9.5%-5.0% 7.0%-5.0%
===============================================================================================================================
42 Wyeth
The assumed health care cost trend rates have a significant effect on the
amounts reported. A one percentage point increase in the assumed health care
cost trend rates would increase the postretirement benefit obligation by $178.8
million and the total service and interest cost components by $16.8 million. A
one percentage point decrease in the assumed health care cost trend rates would
decrease the postretirement benefit obligation by $147.7 million and the total
service and interest cost components by $13.6 million.
Net periodic benefit cost from continuing operations of the Company's
defined benefit plans for 2002, 2001 and 2000 (principally U.S. plans) was as
follows:
COMPONENTS OF NET PERIODIC BENEFIT COST PENSIONS OTHER POSTRETIREMENT BENEFITS
FROM CONTINUING OPERATIONS ----------------------------------- ---------------------------------
(In thousands) 2002 2001 2000 2002 2001 2000
- -------------------------------------------------------------------------------------------------------------------------------
Service cost $ 95,695 $ 78,634 $ 74,656 $ 31,764 $ 24,179 $ 20,460
Interest cost 233,169 226,786 225,248 87,681 76,966 77,666
Expected return on plan assets (236,490) (246,449) (270,131) -- -- --
Amortization of prior service cost 7,146 11,720 10,704 2,003 2,003 330
Amortization of transition obligation 1,057 1,999 2,184 -- -- --
Recognized net actuarial loss 36,798 2,250 2,091 7,164 127 134
- -------------------------------------------------------------------------------------------------------------------------------
Net periodic benefit cost from continuing operations $ 137,375 $ 74,940 $ 44,752 $ 128,612 $ 103,275 $ 98,590
===============================================================================================================================
Net periodic pension benefit cost from continuing operations was higher in
2002 compared with 2001 due primarily to increases in the service cost and the
recognized net actuarial loss of the U.S. pension plans. The recognized net
actuarial loss increased as a result of amortizing the unrecognized net
actuarial loss which represents actuarial losses accumulated through 2001,
primarily resulting from the negative market returns discussed above.
In 2000, as a result of the sale of the Cyanamid Agricultural Products
business, the Company realized a curtailment gain related to the pension plans
of $25.5 million. This curtailment gain was recorded in Loss on disposal of
agricultural products business.
9. Derivative Instruments and Foreign Currency Risk Management Programs
As of January 1, 2001, the Company adopted SFAS Nos. 133 and 138, which require
that all derivative financial instruments be measured at fair value and be
recognized as assets or liabilities on the balance sheet with changes in the
fair value of the derivatives recognized in either income (loss) or accumulated
other comprehensive income (loss), depending on the timing and designated
purpose of the derivative. The fair value of forward contracts and interest rate
swaps reflects the present value of the future potential gain or loss if
settlement were to take place on December 31, 2002, with the fair value of
option contracts reflecting the present value of future cash flows if the
contracts were settled on December 31, 2002. The impact on the Company's
financial position, results of operations and cash flows, upon adoption of these
pronouncements, was immaterial.
The Company currently engages in two primary programs to manage its
exposure to intercompany and third-party foreign currency risk. The two programs
and the corresponding derivative contracts outstanding as of December 31, 2002
were as follows:
1. Short-term foreign exchange forward contracts and swap contracts are
used to neutralize month-end balance sheet exposures. These
contracts essentially take the opposite currency position of that
projected in the month-end balance sheet to counterbalance the
effect of any currency movement. These derivative instruments are
not designated as hedges and are recorded at fair value with any
gains or losses recognized in current period earnings in accordance
with the requirements of SFAS Nos. 133 and 138. The Company recorded
a loss of $88.1 million and a gain of $28.7 million in Other income,
net relating to gains and losses on these foreign exchange forward
contracts and swap contracts for 2002 and 2001, respectively. These
amounts consist of gains and losses from contracts settled during
2002 and 2001, as well as contracts outstanding at December 31, 2002
and 2001 that are recorded at fair value.
2. The Company uses foreign currency put options and foreign currency
forward contracts in its cash flow hedging program to cover foreign
currency risk related to international intercompany inventory sales.
These instruments are designated as cash flow hedges and, in
accordance with SFAS Nos. 133 and 138, any unrealized gains or
losses are included in accumulated other comprehensive income (loss)
with the corresponding asset or liability recorded on the balance
sheet. As of December 31, 2002 and 2001, an after-tax loss of $17.6
million and an after-tax gain of $4.4 million, respectively,
relating to these cash flow hedges were included in Accumulated
other comprehensive loss with the corresponding assets/liabilities
recorded in Other current assets including deferred taxes/Accrued
expenses. The unrealized net losses in Accumulated other
comprehensive loss will be reclassified into the Consolidated
Statement of Operations when the inventory is sold to a third party.
As such, the Company anticipates recognizing
Wyeth 43
these net losses during the next six months. For the years ended
December 31, 2002 and 2001, the Company had losses of $12.1 million
and gains of $33.8 million, respectively, included in Other income,
net relating to these cash flow hedges. Put option contracts
outstanding as of December 31, 2002 expire no later than September
2003.
Occasionally the Company purchases foreign currency put
options outside of the cash flow hedging program to protect
additional intercompany inventory sales. These put options do not
qualify as cash flow hedges under SFAS Nos. 133 and 138 and were
recorded at fair value with all gains or losses, which were not
significant for 2001, recognized in current period earnings. The
Company did not purchase any foreign currency put options outside of
the cash flow hedging program during 2002.
In addition to the programs identified above, the Company has entered into
a foreign exchange forward contract to hedge against foreign exchange
fluctuations on a yen-denominated long-term intercompany loan to the Company's
Japanese subsidiary. The forward contract has been designated as and qualifies
for foreign currency cash flow hedge accounting treatment. As of December 31,
2002 and 2001, the Company had recorded after-tax gains of $3.3 million and $3.5
million, respectively, in Accumulated other comprehensive loss relating to this
foreign exchange forward contract.
The Company also has entered into interest rate swaps to manage interest
rate exposures. The Company strives to achieve a desired balance between
fixed-rate and floating-rate debt and has entered into two effective fair value
interest rate swaps on its $1,500.0 million 6.70% Notes to ensure this desired
balance between fixed-rate and floating-rate debt. The interest rate swaps
effectively converted a portion of the Company's fixed-rate debt into
floating-rate debt. Interest expense on the $1,500.0 million 6.70% Notes is
adjusted to include the payments made or received under the interest rate swap
agreements. The fair value of the swaps relating to the $1,500.0 million 6.70%
Notes, excluding accrued interest, were assets of $200.8 million and $12.8
million as of December 31, 2002 and 2001, respectively. The fair value of these
swaps has been recorded in Other assets including deferred taxes with the
corresponding adjustment recorded to the underlying 6.70% Notes in Long-term
debt.
10. Income Taxes
The provision (benefit) for federal and foreign income taxes from continuing
operations consisted of:
(In thousands)
Years Ended December 31, 2002 2001 2000
- --------------------------------------------------------------------------------
Current:
Federal $ 159,487 $ (96,805) $ 321,484
Foreign 381,018 412,438 292,798
- --------------------------------------------------------------------------------
540,505 315,633 614,282
Deferred:
Federal 1,126,839 270,144 (836,883)
Foreign (17,304) (2,324) 22,601
- --------------------------------------------------------------------------------
1,109,535 267,820 (814,282)
- --------------------------------------------------------------------------------
$ 1,650,040 $ 583,453 $(200,000)
================================================================================
Net deferred tax assets inclusive of valuation allowances for certain
deferred tax assets were reflected on the consolidated balance sheets at
December 31 as follows:
(In thousands) 2002 2001
- --------------------------------------------------------------------------------
Net current deferred tax assets $1,187,451 $1,526,690
Net noncurrent deferred tax assets 802,581 1,583,599
- --------------------------------------------------------------------------------
Net deferred tax assets $1,990,032 $3,110,289
================================================================================
Deferred income taxes are provided for temporary differences between the
financial reporting basis and the tax basis of the Company's assets and
liabilities. Deferred tax assets result principally from the recording of
certain accruals and reserves, which currently are not deductible for tax
purposes, as well as net operating loss carryforwards generated primarily from
deductible payments associated with the Redux and Pondimin diet drug litigation.
Deferred tax liabilities result principally from tax on earnings expected to be
remitted to the United States, the use of accelerated depreciation for tax
purposes, contributions made to the Company's pension plans and taxes to be paid
on expected gains to be realized on selling the remaining shares of Amgen common
stock the Company held at December 31, 2002.
44 Wyeth
The components of the Company's deferred tax assets and liabilities at
December 31 were as follows:
(In thousands) 2002 2001
- --------------------------------------------------------------------------------
Deferred tax assets:
Diet drug product litigation accruals $ 682,927 $ 650,192
Product litigation and environmental
liabilities and other accruals 590,087 660,282
Postretirement, pension and other
employee benefits 579,547 536,676
Net operating loss and other tax
credit carryforwards 1,228,939 1,756,522
Goodwill impairment 48,836 52,837
Restructuring and product discontinuations 128,509 113,638
Inventory reserves 163,936 127,175
Investments and advances 27,685 31,869
Research and development costs 493,303 554,521
Intangibles 63,288 58,538
Other 57,991 40,375
- --------------------------------------------------------------------------------
Total deferred tax assets 4,065,048 4,582,625
================================================================================
Deferred tax liabilities:
Tax on earnings expected to be remitted
to the United States (700,000) (700,000)
Depreciation (343,762) (370,916)
Pension benefits and other employee benefits (345,606) (140,004)
Investments (478,441) --
Equity investments -- (110,204)
Other (158,570) (101,630)
- --------------------------------------------------------------------------------
Total deferred tax liabilities (2,026,379) (1,422,754)
- --------------------------------------------------------------------------------
Deferred tax asset valuation allowances (48,637) (49,582)
- --------------------------------------------------------------------------------
Net deferred tax assets $ 1,990,032 $ 3,110,289
================================================================================
Valuation allowances have been established for certain deferred tax assets
related to environmental liabilities and other operating accruals as the Company
determined that it was more likely than not that these benefits will not be
realized.
The Company has provided $700.0 million of federal income taxes on
unremitted earnings from its international subsidiaries that may be remitted
back to the United States. Federal income taxes were not provided on unremitted
earnings expected to be permanently reinvested internationally. If federal
income taxes were provided, they would approximate $930.0 million.
Reconciliations between the Company's effective tax rate and the U.S.
statutory rate from continuing operations, excluding the diet drug litigation
charges in 2002, 2001 and 2000 (see Note 14), gains relating to Immunex/Amgen
common stock transactions (see Note 2), the effect of the termination fee in
2000 (see Note 3), goodwill impairment in 2000 (see Note 3) and special charges
in 2002 and 2000 (see Note 3), were as follows:
TAX RATE
Years Ended December 31, 2002 2001 2000
- ------------------------------------------------------------------------------
U.S. statutory rate 35.0% 35.0% 35.0%
Effect of Puerto Rico and Ireland
manufacturing operations (10.3) (9.1) (8.6)
Research credits (1.9) (2.1) (1.7)
Goodwill amortization -- 1.2 1.5
Other, net (1.7) (0.9) (0.7)
- ------------------------------------------------------------------------------
Effective tax rate from
continuing operations 21.1% 24.1% 25.5%
==============================================================================
Including the effect of the 2002 litigation charge and special charge
(which had tax benefits of 35.0% and 31.5%, respectively) and gains relating to
Immunex/Amgen common stock transactions (which had a tax provision of 35.6%),
the overall effective tax rate from continuing operations in 2002 was 27.1%.
Including the effect of the 2001 litigation charge (which had a 35.3% tax
benefit), the overall effective tax rate from continuing operations in 2001 was
20.3%. Including the effect of the termination fee and the gain on the sale of
Immunex common stock in 2000 (which had tax provisions of 35.0% and 31.4%,
respectively) and the tax benefits associated with the 2000 litigation charge,
goodwill impairment and special charges (with effective rates of 28.3%, 15.0%
and 35.2%, respectively), the overall effective tax rate from continuing
operations in 2000 was an 18.2% tax benefit.
Total income tax payments, net of tax refunds, for continuing and
discontinued operations in 2002, 2001 and 2000 amounted to $535.8 million,
$493.6 million and $1,038.3 million, respectively.
11. Capital Stock
There were 2,400,000,000 shares of common stock and 5,000,000 shares of
preferred stock authorized at December 31, 2002 and 2001. Of the authorized
preferred shares, there is a series of shares (18,318 and 20,486 outstanding at
December 31, 2002 and 2001, respectively) which is designated as $2.00
convertible preferred stock. Each share of the $2.00 series is convertible at
the option of the holder into 36 shares of common stock. This series may be
called for redemption at $60.00 per share plus accrued dividends.
On October 7, 1999, the Company's Board of Directors declared a dividend
of one preferred share purchase right for each share of common stock outstanding
on October 18, 1999. The rights also apply to all future stock issuances. Each
right permits the holder, under certain circumstances and upon the occurrence of
certain events, to purchase from the Company one one-thousandth of a share of
Series A Junior Participating
Wyeth 45
Preferred Stock of the Company (the Series A Preferred Stock) at an exercise
price of $225 per one one-thousandth of a share of Series A Preferred Stock
under a Rights Plan relating to such Series A Preferred Stock. The 5,000,000
shares of preferred stock authorized will be used for the exercise of any
preferred share purchase rights. The Rights Plan has provisions that are
triggered if any person or group acquires beneficial ownership of 15% or more of
the outstanding common stock or acquires the Company in a merger or other
business combination (an Acquiring Person). In such event, stockholders (other
than the Acquiring Person) would receive stock of the Company or the Acquiring
Person, as the case may be, having a market value of twice the exercise price
along with substantially increased voting and dividend rights, among other
things. The rights expire on October 7, 2009, and prior to there being an
Acquiring Person, the Company may redeem the rights issued under the Rights Plan
for $0.01 per right. The Company can, for as long as the rights are then
redeemable, supplement or amend the Rights Plan in any respect without the
approval of any holders of the rights. At any time after the rights no longer
are redeemable, the Company may supplement or amend the Rights Plan in certain
respects provided that no such supplement or amendment shall adversely affect
the interests of the holders of Rights Certificates as such (other than an
Acquiring Person or an Affiliate or Associate of an Acquiring Person).
Changes in outstanding common shares during 2002, 2001 and 2000 were as
follows:
(In thousands except
shares of preferred stock) 2002 2001 2000
- --------------------------------------------------------------------------------
Balance at January 1 1,320,570 1,311,774 1,303,916
Issued for stock options 7,233 8,550 15,123
Purchases of common stock
for treasury (2,000) -- (7,414)
Conversions of preferred stock
(2,168, 1,462 and 2,293
shares in 2002, 2001 and
2000, respectively) and
other exchanges 252 246 149
- --------------------------------------------------------------------------------
Balance at December 31 1,326,055 1,320,570 1,311,774
================================================================================
The Company has a common stock repurchase program under which the Company
is authorized to repurchase common shares. During 2002, the Company repurchased
2,000,000 shares of common stock. At December 31, 2002, the Company was
authorized to repurchase 4,492,460 common shares in the future.
Shares of common stock held in treasury at December 31, 2002 and 2001 were
96,276,705 and 101,684,219, respectively. The Company has not retired any shares
held in treasury during 2002 and 2001.
12. Stock Options
The Company has five Stock Incentive Plans. Under the Stock Incentive
Plans, options and restricted stock may be granted to purchase a maximum of
246,000,000 shares at prices not less than 100% of the fair market value of the
Company's common stock on the date the option is granted. At December 31, 2002,
there were 54,626,772 shares available for future grants under the Stock
Incentive Plans. No further grants may be made under the Stock Incentive Plan
approved in 1990.
The plans provide for the granting of incentive stock options as defined
under the Internal Revenue Code. Under the plans, grants of non-qualified stock
options with a 10-year term or incentive stock options with a term not exceeding
10 years may be made to selected officers and employees. All stock option grants
vest ratably over a three-year term. The plans also provide for the granting of
stock appreciation rights (SAR), which entitle the holder to receive shares of
the Company's common stock or cash equal to the excess of the market price of
the common stock over the exercise price when exercised. At December 31, 2002,
there were no outstanding SARs.
The Stock Incentive Plans allow for, among other things, the issuance of
up to 32,000,000 shares, in the aggregate, as restricted stock awards.
Restricted stock awards representing 326,510, 290,995 and 148,900 units were
granted in 2002, 2001 and 2000, respectively, to certain employees, including
key executives. Most of these units are converted to shares of restricted stock
based on the achievement of certain performance criteria related to performance
years 2000 through 2006. The remaining units are converted generally at the end
of four years.
Under the Stock Option Plan for Non-Employee Directors, a maximum of
250,000 shares may be granted to non-employee directors at 100% of the fair
market value of the Company's common stock on the date of the grant. Under this
plan, each director who is not a current or former employee receives a grant of
stock options (currently 4,000 options per year) on the day of each annual
meeting, which generally become exercisable on the next annual meeting date.
Stock options granted to non-employee directors were 36,000, 36,000 and 21,000
in 2002, 2001 and 2000, respectively. Shares available for future grants at
December 31, 2002 were 136,000.
Under the 1994 Restricted Stock Plan for Non-Employee Directors, a maximum
of 100,000 restricted shares may be granted to non-employee directors. The
restricted shares granted to each non-employee director are not delivered prior
to the end of a five-year restricted period. At December 31, 2002, 63,200 shares
were available for future grants.
46 Wyeth
Stock option information related to the plans was as follows:
WEIGHTED WEIGHTED WEIGHTED
AVERAGE AVERAGE AVERAGE
EXERCISE EXERCISE EXERCISE
STOCK OPTIONS 2002 PRICE 2001 PRICE 2000 PRICE
- -----------------------------------------------------------------------------------------------------------------------
Outstanding at January 1 100,003,072 $48.57 82,751,313 $43.74 85,244,130 $39.13
Granted 32,907,776 52.29 28,360,196 56.89 16,496,678 56.51
Canceled/forfeited (2,866,185) 56.67 (2,558,655) 57.36 (3,866,134) 58.32
Exercised (2002-$14.52 to
$65.16 per share) (7,232,908) 30.09 (8,549,782) 26.74 (15,123,361) 27.90
- -----------------------------------------------------------------------------------------------------------------------
Outstanding at December 31 122,811,755 50.47 100,003,072 48.57 82,751,313 43.74
=======================================================================================================================
Exercisable at December 31 68,484,510 47.57 57,205,798 41.93 51,830,094 35.31
=======================================================================================================================
The following table summarizes information regarding stock options
outstanding at December 31, 2002:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
- ----------------------------------------------------------------------- -----------------------------
WEIGHTED
AVERAGE WEIGHTED WEIGHTED
RANGE OF NUMBER REMAINING AVERAGE NUMBER AVERAGE
EXERCISE PRICES OUTSTANDING CONTRACTUAL LIFE EXERCISE PRICE EXERCISABLE EXERCISE PRICE
- -----------------------------------------------------------------------------------------------------------
$14.52 to 19.99 8,687,206 1.6 years $17.96 8,687,206 $17.96
20.00 to 29.99 3,208,270 3.2 years 26.35 3,208,270 26.35
30.00 to 39.99 20,886,087 6.8 years 35.48 10,414,279 36.18
40.00 to 49.99 665,280 6.7 years 45.35 466,985 46.15
50.00 to 59.99 49,863,882 7.4 years 55.27 28,739,122 54.34
60.00 to 65.32 39,501,030 8.0 years 61.51 16,968,648 62.29
- -----------------------------------------------------------------------------------------------------------
122,811,755 68,484,510
===========================================================================================================
13. Accumulated Other Comprehensive Loss
Accumulated other comprehensive loss consists of changes in foreign currency
translation adjustments, net unrealized gains (losses) on derivative contracts,
net unrealized gains on marketable securities and minimum pension liability
adjustments. The following table sets forth the changes in each component of
Accumulated other comprehensive loss:
FOREIGN NET UNREALIZED NET UNREALIZED MINIMUM ACCUMULATED
CURRENCY GAINS (LOSSES) GAINS ON PENSION OTHER
TRANSLATION ON DERIVATIVE MARKETABLE LIABILITY COMPREHENSIVE
(In thousands) ADJUSTMENTS(1) CONTRACTS(2) SECURITIES(2) ADJUSTMENTS(2) LOSS
- ----------------------------------------------------------------------------------------------------------------------------------
Balance January 1, 2000 $(614,967) $ -- $ 1,482 $ -- $(613,485)
Period change (70,496) -- 11,422 -- (59,074)
- ----------------------------------------------------------------------------------------------------------------------------------
Balance December 31, 2000 (685,463) -- 12,904 -- (672,559)
Period change (166,200) 7,865 (2,134) -- (160,469)
- ----------------------------------------------------------------------------------------------------------------------------------
Balance December 31, 2001 (851,663) 7,865 10,770 -- (833,028)
Period change 226,797 (22,132) 520,483 (47,691) 677,457
- ----------------------------------------------------------------------------------------------------------------------------------
Balance December 31, 2002 $(624,866) $(14,267) $ 531,253 $(47,691) $(155,571)
==================================================================================================================================
(1) Income taxes are generally not provided for foreign currency translation
adjustments, as such adjustments relate to permanent investments in
international subsidiaries.
(2) Deferred income tax assets (liabilities) provided for net unrealized
(losses) gains on derivative contracts in 2002 and 2001 were $9,500 and
$(1,000), respectively; for net unrealized gains on marketable securities
in 2002 were $(279,200); and for minimum pension liability adjustments in
2002 were $23,390.
Wyeth 47
14. Contingencies and Commitments
The Company is involved in various legal proceedings, including product
liability and environmental matters of a nature considered normal to its
business (see Note 7 for discussion of environmental matters). It is the
Company's policy to accrue for amounts related to these legal matters if it is
probable that a liability has been incurred and an amount is reasonably
estimable.
The Company has been named as a defendant in numerous legal actions
relating to the diet drugs Pondimin (which in combination with phentermine, a
product that was not manufactured, distributed or sold by the Company, was
commonly referred to as "fen-phen") or Redux, which the Company estimated were
used in the United States, prior to their 1997 voluntary market withdrawal, by
approximately 5.8 million people. These actions allege, among other things, that
the use of Redux and/or Pondimin, independently or in combination with
phentermine, caused certain serious conditions, including valvular heart
disease.
On October 7, 1999, the Company announced a nationwide class action
settlement (the settlement) to resolve litigation brought against the Company
regarding the use of the diet drugs Redux or Pondimin. The settlement covers all
claims arising out of the use of Redux or Pondimin, except for claims of primary
pulmonary hypertension (PPH), and is open to all Redux or Pondimin users in the
United States.
On November 23, 1999, U.S. District Judge Louis C. Bechtle granted
preliminary approval of the settlement and directed that notice of the
settlement terms be provided to class members. The notice program began in
December 1999. In early May 2000, the district court held a hearing on the
fairness of the terms of the settlement, with an additional one-day hearing on
August 10, 2000. On August 28, 2000, Judge Bechtle issued an order approving the
settlement. Several appeals were taken from that order to the U.S. Court of
Appeals for the Third Circuit. All but one of those appeals was withdrawn during
2001, and, on August 15, 2001, the Third Circuit affirmed the approval of the
settlement. When no petitions to the U.S. Supreme Court for certiorari were
filed by January 2, 2002, the settlement was deemed to have received final
judicial approval on January 3, 2002.
Under the terms of the nationwide class action settlement, the period
during which class members could register to receive a screening echocardiogram
from the settlement trust ended on August 2, 2002. Those echocardiograms must be
completed by July 3, 2003 unless that date is further extended by the court.
Class members whose trust-supplied echocardiograms demonstrate FDA-positive
levels of heart valve regurgitation (mild or greater aortic valve regurgitation
or moderate or greater mitral valve regurgitation) will have 120 days to elect
either to remain in the settlement or to withdraw from the settlement and
proceed as an intermediate opt out (with specific rights and limitations defined
in the settlement). Class members who chose to obtain their own echocardiogram
outside of the settlement were required to have completed those echocardiograms
by January 3, 2003; the date by which any of those class members whose
echocardiograms show FDA-positive levels of regurgitation must make such an
election is May 3, 2003.
As originally designed, the settlement was composed of two settlement
funds. Fund A (with a present value at the time of settlement of $1,000.0
million) was created to cover refunds, medical screening costs, additional
medical services and cash payments, education and research costs, and
administration costs. Fund A has been fully funded by contributions by the
Company. Fund B (which was to be funded by the Company on an as-needed basis up
to a total of $2,550.0 million) would compensate claimants with significant
heart valve disease. Any funds remaining in Fund A after all Fund A obligations
were met were to be added to Fund B to be available to pay Fund B injury claims.
In December 2002, following a joint motion by the Company and plaintiffs'
counsel, the Court approved an amendment to the settlement agreement which
provided for the merger of Funds A and B into a combined fund which now will
cover all expenses and injury claims in connection with the settlement. The
effect of the merger is to accelerate the spillover of the expected remainder in
Fund A, which now will be available to pay Fund B claims. The merger of the two
funds took place in January 2003.
Payments into the settlement fund may continue, if needed, until 2018.
Payments to the settlement funds in 2002, 2001 and 2000 were $822.7 million,
$936.7 million and $383.0 million, respectively.
Diet drug users choosing to opt out of the settlement class were required
to do so by March 30, 2000. The Company has resolved the claims of all but a
small percentage of these initial opt outs and continues to work toward
resolving those that remain.
The settlement agreement also gives class members who participate in the
settlement the opportunity to opt out of the settlement at two later stages,
although there are restrictions on the nature of claims they can pursue outside
of the settlement. Class members who are diagnosed with certain levels of
valvular regurgitation within a specified time frame can opt out following their
diagnosis and prior to receiving any further benefits under the settlement
(intermediate opt outs). Class members who are diagnosed with certain levels of
regurgitation and who elect to remain in the settlement, but who later develop a
more severe valvular condition, may opt out at the time the more serious
condition develops (back-end opt outs). Under either of these latter two opt out
alternatives, class members may not seek or recover punitive damages, may sue
only for the condition giving rise to the opt out right, and may not rely on
verdicts, judgments or factual findings made in other lawsuits.
On January 18, 2002, as collateral for the Company's financial obligations
under the settlement, the Company established a security fund in the amount of
$370.0 million and recorded such amount in Other assets including deferred
taxes. In April 2002, pursuant to an agreement among the Company, class counsel
and representatives of the settlement trust, an additional $45.0 million (later
reduced to $35.0 million), also included in Other assets including deferred
taxes, was added to the security fund, bringing the total amount in the security
fund to $405.0 million. The amounts in the security fund are owned by the
Company and will earn interest income for the Company while
48 Wyeth
residing in the security fund. The Company will be required to deposit an
additional $180.0 million in the security fund if the Company's credit rating,
as reported by both Moody's and S&P, falls below investment grade.
The Company recorded an initial litigation charge of $4,750.0 million
($3,287.5 million after-tax or $2.51 per share-diluted) in connection with the
Redux and Pondimin litigation in 1999, an additional charge of $7,500.0 million
in 2000 ($5,375.0 million after-tax or $4.11 per share-diluted), a third
litigation charge of $950.0 million ($615.0 million after-tax or $0.46 per
share-diluted) in 2001 and a fourth charge of $1,400.0 million ($910.0 million
after-tax or $0.68 per share-diluted) in the 2002 third quarter. The principal
reason for the charge taken in the 2002 third quarter was that the volume and
size of the claims filed in the nationwide diet drug settlement were greater
than anticipated.
These charges are intended to cover the total amount required to resolve
all diet drug litigation, including anticipated funding requirements for the
nationwide class action settlement, costs to resolve the claims of any members
of the settlement class who in the future may exercise an intermediate or
back-end opt out right, costs to resolve the claims of PPH claimants and initial
opt out claimants, and administrative and litigation expenses.
At December 31, 2002, $1,950.7 million of the litigation accrual remained;
$925.0 million and $1,025.7 million were included in Accrued expenses and Other
noncurrent liabilities, respectively. At December 31, 2001, $1,857.7 million of
the then-existing litigation accrual remained; $1,150.0 million and $707.7
million were included in Accrued expenses and Other noncurrent liabilities,
respectively. Payments to the nationwide class action settlement funds,
individual settlement payments, legal fees and other items were $1,307.0
million, $7,257.9 million and $3,966.8 million for 2002, 2001 and 2000,
respectively.
Based upon the information available at this time, the Company believes
that its reserves will be adequate to cover the remaining obligations relating
to the diet drug litigation. However, in light of the inherent uncertainty in
estimating litigation exposure and the fact that substantial additional
information will become available in the coming months, it is possible that
additional reserves will be required.
The Company is self-insured against ordinary product liability risks and
has liability coverage, in excess of certain limits and subject to certain
policy ceilings, from various insurance carriers.
In the opinion of the Company, although the outcome of any legal
proceedings cannot be predicted with certainty, the ultimate liability of the
Company in connection with its legal proceedings will not have a material
adverse effect on the Company's financial position but could be material to the
results of operations or cash flows in any one accounting period.
COMMITMENTS:
The Company leases certain property and equipment for varying periods under
operating leases. Future minimum rental payments under non-cancelable operating
leases with terms in excess of one year in effect at December 31, 2002 are as
follows:
(In thousands)
- --------------------------------------------------------------------------------
2003 $ 89,698
2004 69,271
2005 64,051
2006 55,355
2007 52,429
Thereafter 60,307
- --------------------------------------------------------------------------------
Total rental commitments $391,111
================================================================================
Rental expense from continuing operations for all operating leases was
$156.0 million, $133.7 million and $128.2 million in 2002, 2001 and 2000,
respectively.
15. Company Data by Segment
The Company has three reportable segments: Pharmaceuticals, Consumer Healthcare
and Corporate. The Company's Pharmaceuticals and Consumer Healthcare reportable
segments are strategic business units that offer different products and
services. The reportable segments are managed separately because they
manufacture, distribute and sell distinct products and provide services, which
require various technologies and marketing strategies.
The Pharmaceuticals segment manufactures, distributes and sells branded
human ethical pharmaceuticals, biologicals, nutritionals, and animal biologicals
and pharmaceuticals. Principal products include women's health care products,
neuroscience therapies, cardiovascular products, nutritionals, gastroenterology
drugs, anti-infectives, vaccines, oncology therapies, musculoskeletal therapies,
hemophilia treatments and immunological products. Principal animal health
products include vaccines, pharmaceuticals, endectocides and growth implants.
The Consumer Healthcare segment manufactures, distributes and sells
over-the-counter health care products that include analgesics,
cough/cold/allergy remedies, nutritional supplements, herbal products, and
hemorrhoidal, antacid, asthma and other relief items.
Corporate is responsible for the treasury, tax and legal operations of the
Company's businesses and maintains and/or incurs certain assets, liabilities,
income, expenses, gains and losses related to the overall management of the
Company which are not allocated to the other reportable segments.
The accounting policies of the segments described above are the same as
those described in "Summary of Significant Accounting Policies" in Note 1. The
Company evaluates the performance of the Pharmaceuticals and Consumer Healthcare
reportable segments based on income from continuing operations before taxes,
which includes gains on the sales of non-corporate assets and certain other
items. Corporate includes interest expense and interest income, gains on the
sales of investments and other corporate assets, gains
Wyeth 49
relating to Immunex/Amgen common stock transactions, the Warner-Lambert Company
termination fee, certain litigation provisions, including the Redux and Pondimin
litigation charges, goodwill impairment, special charges and other miscellaneous
items.
COMPANY DATA BY REPORTABLE SEGMENT
(Dollar amounts in millions)
YEARS ENDED DECEMBER 31, 2002 2001 2000
- --------------------------------------------------------------------------------
NET REVENUE FROM CUSTOMERS(1)
Pharmaceuticals $12,386.6 $11,716.5 $10,772.6
Consumer Healthcare 2,197.4 2,267.2 2,308.7
- --------------------------------------------------------------------------------
Consolidated Total $14,584.0 $13,983.7 $13,081.3
================================================================================
INCOME (LOSS) FROM CONTINUING
OPERATIONS BEFORE TAXES(2)
Pharmaceuticals $ 3,505.5 $ 3,503.5 $ 2,919.5
Consumer Healthcare 608.0 592.1 626.6
Corporate(3) 1,983.7 (1,226.9) (4,647.1)
- --------------------------------------------------------------------------------
Consolidated Total $ 6,097.2 $ 2,868.7 $(1,101.0)
================================================================================
DEPRECIATION AND
AMORTIZATION EXPENSE(2)
Pharmaceuticals $ 434.8 $ 539.1 $ 458.8
Consumer Healthcare 32.1 53.1 61.0
Corporate 17.8 15.5 15.2
- --------------------------------------------------------------------------------
Consolidated Total $ 484.7 $ 607.7 $ 535.0
================================================================================
EXPENDITURES FOR
LONG-LIVED ASSETS(5)
Pharmaceuticals $ 1,789.4 $ 1,827.7 $ 1,720.1
Consumer Healthcare 40.1 67.8 38.4
Corporate 126.3 137.1 55.0
- --------------------------------------------------------------------------------
Consolidated Total $ 1,955.8 $ 2,032.6 $ 1,813.5
================================================================================
TOTAL ASSETS AT DECEMBER 31,
Pharmaceuticals(4) $14,169.8 $13,820.3 $12,388.6
Consumer Healthcare 1,709.8 1,736.3 1,697.2
Corporate 10,115.3 7,411.3 7,006.7
- --------------------------------------------------------------------------------
Consolidated Total $25,994.9 $22,967.9 $21,092.5
================================================================================
COMPANY DATA BY GEOGRAPHIC SEGMENT
(Dollar amounts in millions)
YEARS ENDED DECEMBER 31, 2002 2001 2000
- --------------------------------------------------------------------------------
NET REVENUE FROM CUSTOMERS(1)(5)
United States $ 9,233.8 $ 8,903.2 $ 7,912.8
United Kingdom 750.6 680.2 896.3
Other International 4,599.6 4,400.3 4,272.2
- --------------------------------------------------------------------------------
Consolidated Total $14,584.0 $13,983.7 $13,081.3
================================================================================
LONG-LIVED ASSETS AT DECEMBER 31,(5)
United States $ 7,737.7 $ 7,332.1 $ 6,228.8
Ireland 1,341.0 652.7 386.2
Other International 2,670.2 2,482.6 2,688.6
- --------------------------------------------------------------------------------
Consolidated Total $11,748.9 $10,467.4 $ 9,303.6
================================================================================
(1) The Company adopted new authoritative accounting guidance as of January 1,
2002 reflecting the cost of certain vendor considerations (i.e.,
cooperative advertising payments) as reductions of revenues instead of
selling and marketing expenses. Net revenue for all prior periods
presented has been reclassified to comply with the income statement
classification requirements of the new guidance.
(2) Income (loss) from continuing operations before taxes included goodwill
amortization for 2001 and 2000 as follows: Pharmaceuticals - $136.8 and
$147.8, respectively, and Consumer Healthcare - $23.7 and $31.8,
respectively. The Company ceased amortizing goodwill in accordance with
SFAS No. 142 effective January 1, 2002.
(3) 2002, 2001 and 2000 Corporate included litigation charges of $1,400.0,
$950.0 and $7,500.0, respectively, relating to the litigation brought
against the Company regarding the use of the diet drug products Redux or
Pondimin. The charges are intended to cover all anticipated payments in
connection with the nationwide class action settlement, costs to resolve
the claims of any members of the settlement class who in the future may
exercise an intermediate or back-end opt out right, costs to resolve the
claims of PPH claimants and initial opt out claimants, and administrative
and litigation expenses (see Note 14). The charges related to the
Pharmaceuticals operating segment.
2002 Corporate also included:
- - A gain of $2,627.6 relating to the acquisition of Immunex by Amgen. The
gain represents the excess of $1,005.2 in cash plus the fair value of
98,286,358 Amgen shares received, $2,500.1, over the Company's book basis
of its investment in Immunex and certain transaction costs (see Note 2).
The gain related to the Pharmaceuticals operating segment.
- - A gain of $1,454.6 on the sale of a portion of the Company's Amgen common
stock holdings. The gain was determined by comparing the basis of the
shares sold, $1,782.7, with the net proceeds received, $3,250.8, reduced
by certain related expenses (see Note 2). The gain related to the
Pharmaceuticals operating segment.
- - A special charge of $340.8 for restructuring and related asset impairments
(see Note 3). The charge related to the reportable segments as follows:
Pharmaceuticals - $307.6, Consumer Healthcare - $17.1 and Corporate -
$16.1.
2000 Corporate also included:
- - Income of $1,709.4 resulting from the receipt of an $1,800.0 termination
fee provided for under the merger agreement with Warner-Lambert Company
offset, in part, by certain related expenses (see Note 3).
- - Income of $2,061.2 relating to the Company selling a portion of its
investment in Immunex common stock in a public equity offering with
Immunex (see Note 2). The transaction related to the Pharmaceuticals
operating segment.
- - Goodwill impairment of $401.0 related to the goodwill associated with
generic pharmaceuticals and the Solgar consumer healthcare product line.
The charge related to the operating segments as follows: Pharmaceuticals -
$231.0 and Consumer Healthcare - $170.0 (see Note 3).
- - A special charge of $80.0 related to the voluntary ceasing of production
and subsequent market withdrawal of products containing PPA (see Note 3).
The charge related to the Consumer Healthcare operating segment.
- - A special charge of $267.0 related to costs associated with certain
product discontinuations (see Note 3). The charge related to the
Pharmaceuticals operating segment.
50 Wyeth
(4) 2001 and 2000 included an equity method investment in Immunex of $845.4
and $759.2, respectively. The Company did not retain an equity method
investment in Immunex subsequent to July 15, 2002 (see Note 2).
(5) Other than the United States and the United Kingdom, no other country in
which the Company operates had net revenue of 5% or more of the respective
consolidated total. Other than the United States and Ireland, no country
in which the Company operates had long-lived assets of 5% or more of the
respective consolidated total. The basis for attributing net revenue to
geographic areas is the location of the customer. Long-lived assets
consist of property, plant and equipment, goodwill, other intangibles, and
other assets, excluding deferred taxes, net investments in equity
companies and other investments.
16. Subsequent Events
ISSUANCE OF $1,800.0 MILLION OF NOTES
On February 11, 2003, the Company issued $1,800.0 million of Notes. The issuance
consisted of two tranches of Notes, each of which pay interest semiannually as
follows:
- $300.0 million 4.125% Notes due March 1, 2008 with interest payments
due on March 1 and September 1
- $1,500.0 million 5.25% Notes due March 15, 2013 with interest
payments due on March 15 and September 15
The interest rate payable on both tranches of Notes is subject to an
increase of 0.25 percentage points per level of downgrade in the Company's
credit rating by Moody's or S&P. However, the total adjustment to the interest
rate for either series of Notes cannot exceed two percentage points. There is no
adjustment to the interest rate payable on either series of Notes for the first
single-level downgrade in the Company's credit rating by S&P. The Company would
incur a total of approximately $4.5 million of additional annual interest
expense for every 0.25 percentage point increase in the interest rate. If
Moody's or S&P subsequently were to increase the Company's credit rating, the
interest rate payable on each series of Notes is subject to a decrease of 0.25
percentage points for each level of credit rating increase. The interest rate
payable for both series of Notes cannot be reduced below the original coupon
rate of either series of Notes. In the case of both series of Notes, the
interest rate in effect on March 15, 2006 for such Notes will, thereafter,
become the effective interest rate until maturity.
The Company entered into two interest rate swaps with an aggregate
notional amount of $300.0 million relating to the $300.0 million 4.125% Notes
and two interest rate swaps with an aggregate notional amount of $1,500.0
million relating to the $1,500.0 million 5.25% Notes whereby the Company
effectively converted the fixed rate of interest on these Notes to a floating
rate, which is based on LIBOR.
NEW CREDIT FACILITY
In March 2003, the Company's $3,000.0 million credit facility matured.
Concurrent with this maturity, the Company entered into new credit facilities
totaling $2,700.0 million. These facilities are composed of a $1,350.0 million,
364-day credit facility and a $1,350.0 million three-year credit facility.
The maturity date of any borrowings under the $1,350.0 million, 364-day credit
facility that are outstanding upon its termination in March 2004 is extendible
by the Company for an additional year. The credit facilities contain
substantially identical financial and other covenants, representations,
warranties, conditions and default provisions as the matured facility.
SECURITY FUND DEPOSIT
In February 2003, as required by the amendment to the settlement agreement
merging the two settlement funds (see Note 14), an additional $535.2 million was
added by the Company to the security fund.
Wyeth 51
REPORTS OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Stockholders of Wyeth:
In our opinion, the accompanying consolidated balance sheets as of
December 31, 2002 and 2001, and the related consolidated statements of
operations, of changes in stockholders' equity and of cash flows present fairly,
in all material respects, the financial position of Wyeth and its subsidiaries
at December 31, 2002 and 2001, and the results of their operations and their
cash flows for each of the years then ended in conformity with accounting
principles generally accepted in the United States of America. These financial
statements are the responsibility of the Company's management; our
responsibility is to express an opinion on these financial statements based on
our audits. We conducted our audits of these statements in accordance with
auditing standards generally accepted in the United States of America, which
require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, and evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion. The financial statements of the Company for
the year ended December 31, 2000 were audited by other independent accountants
who have ceased operations. Those independent accountants expressed an
unqualified opinion on those statements in their report dated January 24, 2002.
As discussed in Notes 1 and 5 to the financial statements, on January 1,
2002, the Company adopted Statement of Financial Accounting Standards No. 142,
"Goodwill and Other Intangible Assets."
As discussed above, the financial statements of Wyeth, for the year ended
December 31, 2000, were audited by other independent accountants who have ceased
operations. As described in Note 5, these financial statements have been revised
to include the transitional disclosures required by Statement of Financial
Accounting Standards No. 142. We audited the transitional disclosures described
in Note 5. In our opinion, the transitional disclosures for 2000 in Note 5 are
appropriate. However, we were not engaged to audit, review, or apply any
procedures to the 2000 financial statements of the Company other than with
respect to such disclosures and, accordingly, we do not express an opinion or
any other form of assurance on the 2000 financial statements taken as a whole.
PricewaterhouseCoopers LLP Florham Park, NJ January 27, 2003 except for Note 16
which is as of March 3, 2003
The following is a copy of a report issued by Arthur Andersen LLP and included
in the 2001 Form 10-K report filed on March 29, 2002. This report has not been
reissued by Arthur Andersen LLP and Arthur Andersen LLP has not consented to its
use in this Annual Report on Form 10-K.
To the Board of Directors and Stockholders of Wyeth:
We have audited the accompanying consolidated balance sheets of Wyeth
(formerly American Home Products Corporation--a Delaware corporation) and
subsidiaries as of December 31, 2001* and 2000, and the related consolidated
statements of operations, changes in stockholders' equity and cash flows for
each of the three years in the period ended December 31, 2001.* These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An
audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Wyeth and subsidiaries as of
December 31, 2001* and 2000, and the results of their operations and cash flows
for each of the three years in the period ended December 31, 2001* in conformity
with accounting principles generally accepted in the United States.
Arthur Andersen LLP
New York, New York
January 24, 2002
* Subsequent to the date of this report, the consolidated balance sheet as
of December 31, 2001 and the related consolidated statements of
operations, changes in stockholders' equity and cash flows for the year
then ended were audited by PricewaterhouseCoopers LLP, whose report
appears above.
52 Wyeth
MANAGEMENT REPORT ON FINANCIAL STATEMENTS
Management has prepared and is responsible for the Company's consolidated
financial statements and related notes to consolidated financial statements.
They have been prepared in accordance with accounting principles generally
accepted in the United States and necessarily include amounts based on judgments
and estimates made by management. All financial information in this Annual
Report is consistent with the consolidated financial statements.
The Company maintains internal accounting control systems and related
policies and procedures designed to provide reasonable assurance that assets are
safeguarded, that transactions are executed in accordance with management's
authorization and are properly recorded, and that accounting records may be
relied upon for the preparation of consolidated financial statements and other
financial information. The design, monitoring and revision of internal
accounting control systems involve, among other things, management's judgment
with respect to the relative cost and expected benefits of specific control
measures. The Company also maintains an internal auditing function, which
evaluates and formally reports on the adequacy and effectiveness of internal
accounting controls, policies and procedures.
The Company's consolidated financial statements have been audited by
independent accountants who have expressed their opinion with respect to the
fairness of these statements.
The Audit Committee of the Board of Directors, composed of non-employee
directors, meets periodically with the independent accountants and internal
auditors to evaluate the effectiveness of the work performed by them in
discharging their respective responsibilities and to assure their independent
and free access to the Committee.
Robert Essner Kenneth J. Martin
Chairman, President and Executive Vice President and
Chief Executive Officer Chief Financial Officer
Wyeth 53
QUARTERLY FINANCIAL DATA (UNAUDITED)
First Quarter Second Quarter Third Quarter Fourth Quarter
(In thousands except per share amounts) 2002 2002 2002 2002
- ---------------------------------------------------------------------------------------------------------------
Net revenue $3,643,521 $3,502,848 $3,623,672 $3,813,994
Gross profit 2,841,342 2,615,633 2,565,550 2,643,123
Net income(1) 871,920 599,859 1,401,399 1,574,027
Diluted earnings per share(1) 0.65 0.45 1.05 1.18
First Quarter Second Quarter Third Quarter Fourth Quarter
(In thousands except per share amounts) 2001 2001 2001 2001
- ---------------------------------------------------------------------------------------------------------------
Net revenue(3) $3,417,284 $3,183,393 $3,699,600 $3,683,468
Gross profit(3) 2,618,681 2,392,352 2,819,678 2,764,258
Net income(2) 733,554 476,996 252,072 822,672
Diluted earnings per share(2) 0.55 0.36 0.19 0.62
(1) Third Quarter 2002 included a gain of $1,684,700 after-tax or $1.26 per
share-diluted relating to the acquisition of Immunex by Amgen and a
litigation charge of $910,000 after-tax or $0.68 per share-diluted to
increase the reserve relating to the litigation brought against the
Company regarding the use of the diet drugs Redux or Pondimin.
Fourth Quarter 2002 included a gain of $943,401 after-tax or $0.71 per
share-diluted on the sales of 67,050,400 shares of Amgen common stock and
a special charge of $233,500 after-tax or $0.18 per share-diluted for
restructuring and related asset impairments.
(2) Third Quarter 2001 included a litigation charge of $615,000 after-tax or
$0.46 per share-diluted in connection with the litigation brought against
the Company regarding the use of the diet drugs Redux or Pondimin.
(3) First, Second, Third and Fourth Quarters 2001 were restated to reflect the
adoption of new authoritative accounting guidance as of January 1, 2002
recognizing the cost of certain vendor considerations (i.e., cooperative
advertising payments) as reductions of revenues instead of selling and
marketing expenses.
MARKET PRICES OF COMMON STOCK AND DIVIDENDS
2002 Range of Prices* 2001 Range of Prices*
---------------------------------- ----------------------------------
Dividends Dividends
High Low per Share High Low per Share
- --------------------------------------------------------------------------------------------------
First quarter $66.51 $60.48 $ 0.23 $62.50 $52.00 $ 0.23
Second quarter 66.49 49.00 0.23 63.80 54.06 0.23
Third quarter 52.24 28.25 0.23 62.31 53.20 0.23
Fourth quarter 39.39 31.25 0.23 62.25 55.70 0.23
* Prices are those of the New York Stock Exchange-- Composite Transactions.
54 Wyeth
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
The following commentary should be read in conjunction with the consolidated
financial statements and notes to consolidated financial statements on pages 28
to 51.
RESULTS OF OPERATIONS
The Company adopted new authoritative accounting guidance as of January 1, 2002
reflecting the cost of certain vendor considerations (i.e., cooperative
advertising payments) as reductions of revenues instead of selling and marketing
expenses. Financial information for all prior periods presented has been
reclassified to comply with the income statement classification requirements of
the new guidance. These reclassifications had no effect on total net revenue
growth between the periods presented.
NET REVENUE
Worldwide net revenue increased 4% to $14.6 billion for 2002. Worldwide net
revenue increased 7% to $14.0 billion for 2001. The following table sets forth
2002, 2001 and 2000 worldwide net revenue by operating segment together with the
percentage changes in worldwide net revenue from prior years:
YEARS ENDED DECEMBER 31, 2002 VS. 2001 2001 VS. 2000
(In millions) ------------------------------------------- % INCREASE % INCREASE
Net Revenue 2002 2001 2000 (DECREASE) (DECREASE)
- -----------------------------------------------------------------------------------------------------------------
Operating Segment:
Pharmaceuticals $12,386.6 $11,716.5 $10,772.6 6% 9%
Consumer Healthcare 2,197.4 2,267.2 2,308.7 (3)% (2)%
- -----------------------------------------------------------------------------------------------------------------
Consolidated Net Revenue $14,584.0 $13,983.7 $13,081.3 4% 7%
=================================================================================================================
2002 vs. 2001
Worldwide pharmaceutical net revenue increased 6% (7% for human pharmaceuticals)
for 2002. There was no foreign exchange impact on worldwide pharmaceutical net
revenue for 2002. U.S. pharmaceutical net revenue increased 5% for 2002 due
primarily to higher sales of Protonix, Effexor, Rapamune and ReFacto and
alliance revenue offset, in part, by lower sales of Premarin family products,
Prevnar, animal health products and generic products (due to the discontinuance
of certain oral generics). The decline in animal health products revenues was
due primarily to lower sales and higher-than-projected returns of ProHeart 6, a
single dose, canine heartworm preventative product, offset, in part, by higher
sales of the Company's West Nile virus biological vaccine for horses, which was
introduced in the 2001 third quarter. Refer to "Certain Factors That May Affect
Future Results" herein for additional discussion relating to Premarin family
products and Prevnar.
International pharmaceutical net revenue increased 6% for 2002 due
primarily to higher sales of Effexor, Prevnar, Enbrel (for which the Company has
exclusive marketing rights outside of North America), Rapamune and ReFacto
offset, in part, by lower sales of Premarin family products.
Worldwide consumer healthcare net revenue decreased 3% for 2002. There was
no foreign exchange impact on worldwide consumer healthcare net revenue for
2002. U.S. consumer healthcare net revenue decreased 5% for 2002 as a result of
lower sales of cough/cold/allergy products, Advil and Denorex, which was
divested in February 2002, partially offset by higher sales of Centrum and
initial sales of Alavert, which was introduced in the 2002 fourth quarter.
International consumer healthcare net revenue was flat for 2002 as lower
sales of cough/cold/allergy products and Caltrate were offset by higher sales of
Advil.
Wyeth 55
2001 vs. 2000
Worldwide pharmaceutical net revenue increased 9% (10% for human
pharmaceuticals) for 2001. Excluding the negative impact of foreign exchange,
worldwide pharmaceutical net revenue increased 11% for 2001. U.S. pharmaceutical
net revenue increased 15% for 2001 due primarily to higher sales of Protonix
(introduced in the 2000 second quarter), Prevnar (introduced in the 2000 first
quarter), Effexor (as a result of higher volume and market share of new
prescriptions as well as expanded indications), Premarin family products,
Cordarone I.V. and alliance revenue offset, in part, by lower sales of Ziac (due
to generic competition) and generic products (due to the discontinuance of
certain oral generics).
International pharmaceutical net revenue decreased 1% for 2001 due
primarily to lower sales of Meningitec and animal health products offset, in
part, by higher sales of Effexor (as a result of higher volume and market share
of new prescriptions as well as expanded indications), Enbrel, Zoton and
nutritionals. Sales of Meningitec, the Company's meningococcal meningitis
vaccine, decreased as compared with the prior year, as it was used in 2000 to
vaccinate nearly all children and adolescents in the United Kingdom. The decline
in animal health products revenues was due primarily to a general continued
weakening in the livestock markets and continuing concerns about foot-and-mouth
and mad cow diseases.
Worldwide consumer healthcare net revenue decreased 2% for 2001. Excluding
the negative impact of foreign exchange, worldwide consumer healthcare net
revenue was unchanged for 2001. U.S. consumer healthcare net revenue decreased
1% for 2001 as a result of lower sales of cough/ cold/allergy products and
Flexagen offset by higher sales of Chap Stick, Caltrate and Advil.
International consumer healthcare net revenue decreased 3% for 2001 due
primarily to the divestiture of two international non-core products which
occurred early in 2001, as well as lower sales of cough/cold/allergy products.
These decreases were partially offset by higher sales of Centrum products,
Caltrate and Advil.
The following table sets forth the significant 2002, 2001 and 2000
pharmaceutical and consumer healthcare worldwide net revenue by product:
PHARMACEUTICALS
- ----------------------------------------------------------------------------------
(In millions)
PRODUCTS 2002 2001 2000
- ----------------------------------------------------------------------------------
Effexor $ 2,072.3 $ 1,542.0 $ 1,159.1
Premarin family 1,879.9 2,073.5 1,870.2
Protonix 1,070.8 561.3 145.0
Nutritionals 834.7 823.5 776.0
Prevnar 647.5 798.2 460.6
Oral contraceptives 576.3 703.4 738.5
Zosyn/Tazocin 406.1 439.8 384.5
Zoton 309.4 284.1 233.9
Cordarone 283.2 269.6 203.2
BenFIX 219.2 212.8 180.0
Ativan 217.2 232.7 246.1
Synvisc 212.5 188.3 179.3
ReFacto 197.5 147.3 91.1
Generics 187.4 309.8 444.6
Enbrel 158.8 93.9 37.6
Rapamune 129.7 70.2 26.5
Minocin 117.1 122.1 147.2
Meningitec 90.1 78.6 322.6
Ziac/Zebeta 64.1 70.0 283.7
Animal health 653.3 776.2 793.0
Alliance revenue 418.8 322.4 188.3
Other 1,640.7 1,596.8 1,861.6
- ----------------------------------------------------------------------------------
Total pharmaceuticals $12,386.6 $11,716.5 $10,772.6
==================================================================================
CONSUMER HEALTHCARE
- ----------------------------------------------------------------------------------
(In millions)
PRODUCTS 2002 2001 2000
- ----------------------------------------------------------------------------------
Centrum $ 516.2 $ 503.3 $ 486.8
Advil* 442.7 453.7 451.4
Cough/cold/allergy products 463.9 529.7 538.0
Caltrate 142.4 148.3 133.8
Chap Stick 111.3 110.0 98.3
Alavert 8.5 -- --
Denorex 0.8 16.9 18.0
Other 511.6 505.3 582.4
- ----------------------------------------------------------------------------------
Total consumer healthcare $ 2,197.4 $ 2,267.2 $ 2,308.7
==================================================================================
* Advil Cold & Sinus family and Children's Advil family are included within
the cough/cold/allergy product line.
56 Wyeth
The following table sets forth the percentage changes in 2002 and 2001
worldwide net revenue by operating segment and geographic area compared with the
prior year, including the effect volume, price and foreign exchange had on these
percentage changes:
% INCREASE (DECREASE) % INCREASE (DECREASE)
YEAR ENDED DECEMBER 31, 2002 YEAR ENDED DECEMBER 31, 2001(1)
------------------------------------------- ----------------------------------------------
FOREIGN TOTAL NET FOREIGN TOTAL NET
VOLUME PRICE EXCHANGE REVENUE VOLUME PRICE EXCHANGE REVENUE
- -------------------------------------------------------------------- ----------------------------------------------
PHARMACEUTICALS
United States (2)% 7% -- 5% 10% 5% -- 15%
International 5% 1% -- 6% 4% 1% (6)% (1)%
- -------------------------------------------------------------------- ----------------------------------------------
Total 1% 5% -- 6% 8% 3% (2)% 9%
==================================================================== ==============================================
CONSUMER HEALTHCARE
United States (6)% 1% -- (5)% (3)% 2% -- (1)%
International (1)% 2% (1)% -- (1)% 3% (5)% (3)%
- -------------------------------------------------------------------- ----------------------------------------------
Total (4)% 1% -- (3)% (2)% 2% (2)% (2)%
==================================================================== ==============================================
TOTAL
United States (2)% 6% -- 4% 8% 4% -- 12%
International 4% 1% -- 5% 4% 1% (6)% (1)%
- -------------------------------------------------------------------- ----------------------------------------------
Total -- 4% -- 4% 6% 3% (2)% 7%
==================================================================== ==============================================
(1) 2001 was restated to reflect the adoption of new authoritative accounting
guidance as of January 1, 2002 recognizing the cost of certain vendor
considerations (i.e., cooperative advertising payments) as reductions of
revenues instead of selling and marketing expenses.
OPERATING EXPENSES
2002 vs. 2001
COST OF GOODS SOLD, as a percentage of Net revenue, increased to 26.9% for 2002
compared with 24.2% for 2001. Excluding alliance revenue, cost of goods sold, as
a percentage of net sales, for 2002 was 27.7%, a 2.9% increase from 24.8% in
2001. The decline in margin was due primarily to a less profitable product mix
as a result of lower sales of higher margin products (e.g., Premarin family and
Prevnar) and higher sales of lower margin products (e.g., Protonix, ReFacto,
Centrum products) in both the pharmaceuticals and consumer healthcare segments,
combined with increased costs associated with addressing various manufacturing
issues.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES, as a percentage of Net
revenue, decreased to 34.4% for 2002 compared with 34.9% for 2001 (excluding the
effect of goodwill amortization from 2001). The slightly lower ratio of selling,
general and administrative expenses resulted from significant cost-containment
efforts directed specifically at marketing expenses in the pharmaceuticals and
consumer healthcare segments offset, in part, by higher selling expenses related
to an expansion in the global sales force.
RESEARCH AND DEVELOPMENT EXPENSES increased 11% for 2002 due primarily to
increased head count, clinical grant spending, cost-sharing expenditures
relating to pharmaceutical collaborations and other research operating expenses
(including higher chemical and material costs) offset, in part, by lower
payments under licensing agreements. Pharmaceutical research and development
expenditures accounted for 95%, 96% and 96% of total research and development
expenditures in 2002, 2001 and 2000, respectively. Pharmaceutical research and
development expenses, as a percentage of worldwide pharmaceutical net revenue,
exclusive of nutritional sales and alliance revenue, were 18%, 17% and 16% in
2002, 2001 and 2000, respectively.
2001 vs. 2000
COST OF GOODS SOLD, as a percentage of Net revenue, decreased to 24.2% for
2001 compared with 25.0% for 2000. Excluding alliance revenue, cost of goods
sold, as a percentage of net sales, for 2001 was 24.8%, a 0.6% decrease from
25.4% in 2000. The margin improvement resulted from a more profitable mix as a
result of increased sales of higher margin products in both the pharmaceuticals
and consumer healthcare segments and lower royalty expenses offset, in part, by
increased costs associated with improving the U.S. technical operations and
product supply processes.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES, as a percentage of Net
revenue, decreased to 36.0% for 2001 compared with 37.1% for 2000. The lower
ratio of selling, general and administrative expenses resulted from
non-recurring launch expenses, primarily media, related to pharmaceutical
product launches in 2000 and lower co-promotion expenses for Ziac due to reduced
sales as a result of generic competition. This ratio improvement was partially
offset by an increase in selling and marketing expenses in the Company's animal
health division to support the domestic launch of ProHeart 6, a new single dose,
canine heartworm preventative product.
RESEARCH AND DEVELOPMENT EXPENSES increased 11% for 2001 due primarily to
increased head count, ongoing clinical trials of pharmaceuticals in several
therapeutic categories and other research operating expenses (including higher
chemical and material costs). These increases were partially offset by lower
costs resulting from the timing of payments pursuant to certain pharmaceutical
collaborations and lower payments under licensing agreements.
INTEREST EXPENSE AND OTHER INCOME
2002 vs. 2001
Interest expense, net increased 38% for 2002 due primarily to lower interest
income as compared with 2001. Weighted
Wyeth 57
average debt outstanding during 2002 and 2001 was $10,155.2 million and $7,283.7
million, respectively. However, the impact of higher weighted average debt
outstanding was offset by lower interest rates on outstanding commercial paper
and capitalized interest relating to capital projects.
OTHER INCOME, NET increased 40% for 2002 primarily as a result of the
Company completing the sale of certain of its assets relating to the generic
human injectables product line, which resulted in a gain of $172.9 million
($108.9 million after-tax or $0.08 per share-diluted). In addition, the Company
received proceeds from a settlement regarding price fixing by certain vitamin
suppliers offset, in part, by lower equity income and the non-recurrence of
income received in 2001 related to the divestiture of certain product rights.
2001 vs. 2000
INTEREST EXPENSE, NET increased substantially for 2001 due primarily to higher
weighted average debt outstanding as compared with 2000. Weighted average debt
outstanding during 2001 and 2000 was $7,283.7 million and $3,853.0 million,
respectively. The increase in interest expense was partially offset by higher
capitalized interest resulting from additional capital projects, recognized
during 2001, and lower interest rates on outstanding commercial paper.
OTHER INCOME, NET increased 70% for 2001 due primarily to lower
non-recurring charges as compared with 2000 (including payments for access to
various pharmaceutical collaborations, costs associated with a consent decree
entered into with the U.S. Food and Drug Administration (FDA) and costs related
to a product discontinuation), higher gains on the sales of non-strategic assets
and higher equity income.
2002, 2001 AND 2000 UNUSUAL TRANSACTIONS
GAINS RELATED TO IMMUNEX/AMGEN COMMON STOCK TRANSACTIONS
In the 2002 fourth quarter, the Company recorded a gain of $1,454.6 million
($943.4 million after-tax or $0.71 per share-diluted) from the sales of
67,050,400 shares of Amgen Inc.'s (Amgen) common stock, received in connection
with Amgen's acquisition of Immunex Corporation (Immunex), resulting in net
proceeds of $3,250.8 million. The gain was determined by comparing the basis of
the shares sold of $1,782.7 million with the net proceeds received reduced by
certain related expenses (see Note 2 to the consolidated financial statements).
In the 2002 third quarter, the Company recorded a gain of $2,627.6 million
($1,684.7 million after-tax or $1.26 per share-diluted) relating to the
acquisition of Immunex by Amgen. The gain represents the excess of $1,005.2
million in cash plus the fair value of 98,286,358 Amgen shares received,
$2,500.1 million, over the Company's book basis of its investment in Immunex and
certain transaction costs. The gain on the shares exchanged is based on the
quoted market price of Amgen common stock on July 15, 2002 (the closing date)
reduced by a discount for certain stock marketability restrictions (see Note 2
to the consolidated financial statements).
In November 2000, the Company and Immunex completed a public equity
offering in which the Company sold 60.5 million shares of Immunex common stock.
Proceeds to the Company were $2,404.9 million, resulting in a gain on the sale
of $2,061.2 million ($1,414.9 million after-tax or $1.08 per share-diluted). The
Company used the net proceeds from this sale to reduce outstanding commercial
paper and for other general corporate purposes (see Note 2 to the consolidated
financial statements).
LITIGATION CHARGES
In the 2002 third quarter, the Company recorded a charge of $1,400.0 million
($910.0 million after-tax or $0.68 per share-diluted) to increase the reserve
relating to the Pondimin (which in combination with phentermine, a product that
was not manufactured, distributed or sold by the Company, was commonly referred
to as "fen-phen") and Redux diet drug litigation. The principal reason for this
charge was that the volume and size of the claims filed in the nationwide diet
drug settlement were greater than anticipated. An initial litigation charge of
$4,750.0 million ($3,287.5 million after-tax or $2.51 per share-diluted) was
recorded in the 1999 third quarter followed by an additional litigation charge
of $7,500.0 million ($5,375.0 million after-tax or $4.11 per share-diluted)
recorded in the 2000 fourth quarter and a third litigation charge of $950.0
million ($615.0 million after-tax or $0.46 per share-diluted) recorded during
the 2001 third quarter. These charges are intended to cover the total amount
required to resolve all diet drug litigation, including anticipated funding
requirements for the nationwide class action settlement and costs to resolve the
claims of any members of the settlement class who in the future may exercise an
intermediate or back-end opt out right. Additionally, these charges will cover
any remaining administrative and legal expenses and costs associated with the
resolution of the claims of the remaining initial opt outs and primary pulmonary
hypertension (PPH) claimants (see Note 14 to the consolidated financial
statements and the "Liquidity, Financial Condition and Capital Resources"
section herein for further discussion relating to the Company's additional
financing requirements for the future settlement payments).
SPECIAL CHARGES
In the 2002 fourth quarter, the Company recorded a special charge for
restructuring and related asset impairments of $340.8 million ($233.5 million
after-tax or $0.18 per share-diluted). The restructuring charge and related
asset impairments were recorded to recognize the costs of closing certain
manufacturing facilities and two research facilities, as well as the elimination
of certain positions at the Company's facilities. The closing of the
manufacturing and research facilities and reduction of sales and
administrative-related positions cover approximately 3,150 employees worldwide
(see Note 3 to the consolidated financial statements).
58 Wyeth
In November 2000, in accordance with an FDA request, the Company
immediately ceased global production and shipments of any products containing
phenylpropanolamine (PPA) and voluntarily withdrew any such products from
customer warehouses and retail store shelves. As a result, the Company recorded
a special charge of $80.0 million ($52.0 million after-tax or $0.04 per
share-diluted) to provide primarily for product returns and the write-off of
inventory (see Note 3 to the consolidated financial statements).
During the 2000 fourth quarter, the Company recorded a special charge of
$267.0 million ($173.0 million after-tax or $0.13 per share-diluted) related to
the discontinuation of certain products. The special charge provided for fixed
asset impairments, inventory write-offs, severance obligations, idle plant costs
and contract termination costs (see Note 3 to the consolidated financial
statements).
At December 31, 2000, the Company performed goodwill and other intangible
reviews and noted that projected profitability and future cash flows associated
with generic pharmaceuticals and the Solgar consumer healthcare product line
would not be sufficient to recover the remaining goodwill related to these
product lines. As a result, the Company recorded a special charge of $401.0
million ($341.0 million after-tax or $0.26 per share-diluted) to write down the
carrying value of goodwill related to these product lines, to fair value,
representing discounted future cash flows (see Note 3 to the consolidated
financial statements).
TERMINATION FEE
During the 2000 first quarter, the Company and Warner-Lambert Company terminated
their merger agreement. The Company recorded income of $1,709.4 million
($1,111.1 million after-tax or $0.85 per share-diluted) resulting from the
receipt of an $1,800.0 million termination fee provided for under the merger
agreement offset, in part, by certain related expenses (see Note 3 to the
consolidated financial statements).
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE TAXES
The following table sets forth worldwide income (loss) from continuing
operations before taxes by operating segment together with the percentage
changes from the comparable periods in the prior year:
2002 VS. 2001 2001 VS. 2000
(Dollar amounts in millions) YEARS ENDED DECEMBER 31, ------------- -------------
Income (Loss) from Continuing --------------------------------------------- % INCREASE
Operations before Taxes(1) 2002 2001 2000 % INCREASE (DECREASE)
- -------------------------------------------------------------------------------------------------------------------
Operating Segment:
Pharmaceuticals $3,505.5 $3,503.5 $2,919.5 -- 20%
Consumer Healthcare 608.0 592.1 626.6 3% (6)%
- -------------------------------------------------------------------------------------------------------------------
4,113.5 4,095.6 3,546.1 -- 15%
Corporate(2) 1,983.7 (1,226.9) (4,647.1) -- (74)%
- -------------------------------------------------------------------------------------------------------------------
Total(3) $6,097.2 $2,868.7 $(1,101.0) -- --
===================================================================================================================
(1) Income (loss) from continuing operations before taxes included goodwill
amortization for 2001 and 2000 as follows: Pharmaceuticals--$136.8 and
$147.8, respectively, and Consumer Healthcare--$23.7 and $31.8,
respectively. The Company ceased amortizing goodwill in accordance with
SFAS No. 142 effective January 1, 2002. Excluding goodwill amortization
from the 2001 and 2000 results, Pharmaceuticals and Consumer Healthcare
income (loss) from continuing operations before taxes decreased 4% and 1%,
respectively, for 2002 and increased 19% and decreased 6%, respectively,
for 2001.
(2) 2002, 2001 and 2000 Corporate included litigation charges of $1,400.0,
$950.0 and $7,500.0, respectively, relating to the litigation brought
against the Company regarding the use of the diet drugs Redux or Pondimin.
These charges are intended to cover all anticipated payments in connection
with the nationwide class action settlement, costs to resolve the claims
of any members of the settlement class who in the future may exercise an
intermediate or back-end opt out right, costs to resolve the claims of PPH
claimants and initial opt out claimants, and administrative and litigation
expenses.
2002 Corporate also included:
- A gain of $2,627.6 relating to the acquisition of Immunex by
Amgen. The gain represents the excess of $1,005.2 in cash plus
the fair value of 98,286,358 Amgen shares received, $2,500.1,
over the Company's book basis of its investment in Immunex and
certain transaction costs.
- A gain of $1,454.6 from the sales of 67,050,400 shares of
Amgen common stock. The gain was determined by comparing the
basis of the shares sold, $1,782.7, with the net proceeds
received, $3,250.8, reduced by certain related expenses.
- A special charge of $340.8 for restructuring and related asset
impairments.
2000 Corporate also included:
- Income of $1,709.4 resulting from the receipt of an $1,800.0
termination fee provided for under the merger agreement with
Warner-Lambert Company offset, in part, by certain related
expenses.
- Income of $2,061.2 related to the Company selling a portion of
its investment in Immunex common stock in a public equity
offering with Immunex.
- Goodwill impairment of $401.0 related to the goodwill
associated with generic pharmaceuticals and the Solgar
consumer healthcare product line.
- A special charge of $80.0 related to the voluntary ceasing of
production and subsequent market withdrawal of products
containing PPA.
- A special charge of $267.0 related to costs associated with
certain product discontinuations.
Excluding the 2002, 2001 and 2000 litigation charges, 2002 and 2000 gains
relating to Immunex/Amgen common stock transactions, 2000 termination fee,
2000 goodwill impairment, and 2002 and 2000 special charges, Corporate
expenses, net increased 29% and 63% for 2002 and 2001, respectively.
(3) Excluding the 2002, 2001 and 2000 litigation charges, 2002 and 2000 gains
relating to Immunex/Amgen common stock transactions, 2000 termination fee,
2000 goodwill impairment, and 2002 and 2000 special charges, total income
(loss) from continuing operations before taxes decreased 2% for 2002 and
increased 13% for 2001.
Wyeth 59
The following explanations of changes in income (loss) from continuing
operations before taxes, by operating segment, for 2002 compared with 2001 and
2001 compared with 2000, exclude items listed in footnote (2) to the table
above.
PHARMACEUTICALS
Worldwide pharmaceutical income from continuing operations before taxes
decreased 4% (less than 1% for human pharmaceuticals) for 2002, excluding 2001
goodwill amortization, due to higher cost of goods sold, as a percentage of net
revenue, and higher research and development expenses offset, in part, by higher
worldwide net revenue. Higher research and development expenses were primarily
due to increased head count, clinical grant spending, cost-sharing expenditures
relating to pharmaceutical collaborations and other research operating expenses
(including higher chemical and material costs) offset, in part, by lower
payments under licensing agreements.
Worldwide pharmaceutical income from continuing operations before taxes
increased 19% (20% for human pharmaceuticals) for 2001, excluding goodwill
amortization from the 2001 and 2000 results, due primarily to higher U.S. net
revenue (favorable product mix) and other income, net (primarily lower
non-recurring charges and higher gains on asset sales) offset, in part, by
higher selling, general and administrative expenses and research and development
expenses. Higher selling, general and administrative expenses were due primarily
to increased promotional expenses to support existing product lines and sales
force expansion offset, in part, by a decrease in marketing expenses related to
product launches that occurred in 2000.
CONSUMER HEALTHCARE
Worldwide consumer healthcare income from continuing operations before taxes
decreased 1% for 2002, excluding 2001 goodwill amortization, due primarily to
lower U.S. sales and higher research and development expenses offset, in part,
by higher other income, net (primarily attributable to the proceeds received
from a settlement regarding price fixing by certain vitamin suppliers).
Worldwide consumer healthcare income from continuing operations before taxes
decreased 6% for 2001, excluding goodwill amortization from the 2001 and 2000
results, due primarily to lower worldwide sales and lower other income, net
(primarily lower gains on sales of non-strategic assets).
CORPORATE
Corporate expenses, net increased 29% for 2002 due primarily to higher general
and administrative expenses and interest expense, net resulting from lower
interest income during 2002. Corporate expenses, net increased 63% for 2001 due
primarily to higher interest expense, net and lower other income, net related to
an insurance recovery of environmental costs recorded in 2000 offset, in part,
by lower general and administrative expenses.
EFFECTIVE TAX RATE
The effective tax rates for 2002, 2001 and 2000 were 21.1%, 23.3% and 24.4%,
respectively (excluding the effect of goodwill amortization in 2001 and 2000 and
the unusual items identified below). The downward trend in the effective tax
rates was due primarily to an increased benefit from manufacturing in lower tax
jurisdictions.
60 Wyeth
INCOME (LOSS) AND DILUTED EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS
Income and diluted earnings per share from continuing operations in 2002
increased to $4,447.2 million and $3.33 compared with $2,285.3 million and $1.72
for 2001, respectively. Loss and diluted loss per share from continuing
operations in 2000 were $901.0 million and $0.69, respectively. Income (loss)
from continuing operations for 2002, 2001 and 2000 included the following
unusual items:
DILUTED EARNINGS (LOSS)
(Dollar amounts in millions INCOME (LOSS) PER SHARE FROM
except per share amounts) FROM CONTINUING OPERATIONS CONTINUING OPERATIONS
----------------------------------------- ------------------------------------------
Years Ended December 31, 2002 2001 2000 2002 2001 2000
- -----------------------------------------------------------------------------------------------------------------------------------
Income from continuing operations
before unusual items and
including the dilutive effect of
common stock equivalents (CSE) $ 2,962.6 $ 2,900.3 $ 2,514.0 $ 2.22 $ 2.18 $ 1.90
Dilutive effect of CSE(1) -- -- -- -- -- 0.02
- -----------------------------------------------------------------------------------------------------------------------------------
$ 2,962.6 $ 2,900.3 $ 2,514.0 $ 2.22 $ 2.18 $ 1.92
Warner-Lambert Company
termination fee -- -- 1,111.1 -- -- 0.85
Gains related to Immunex/Amgen
common stock transactions(2) 2,628.1 -- 1,414.9 1.97 -- 1.08
Redux and Pondimin diet drug
litigation charges (910.0) (615.0) (5,375.0) (0.68) (0.46) (4.11)
Goodwill impairment -- -- (341.0) -- -- (0.26)
Special charges:
Restructuring charge and related
asset impairments (233.5) -- -- (0.18) -- --
Voluntary market withdrawals -- -- (52.0) -- -- (0.04)
Product discontinuations -- -- (173.0) -- -- (0.13)
- -----------------------------------------------------------------------------------------------------------------------------------
$ 4,447.2 $ 2,285.3 $ (901.0) $ 3.33 $ 1.72 $ (0.69)
===================================================================================================================================
(1) The $0.02 per share benefit represents the impact on income from
continuing operations of excluding the dilutive effect of CSE. 2001
diluted earnings per share from continuing operations of $2.18 includes
the dilutive impact of CSE.
(2) The gains related to the Immunex/Amgen common stock transactions consist
of the following:
- $2,627.6 ($1,684.7 after-tax or $1.26 per share-diluted)
recorded during the 2002 third quarter relating to the
acquisition of Immunex by Amgen. The gain represents the
excess of $1,005.2 in cash plus the fair value of 98,286,358
Amgen shares received, $2,500.1, over the Company's book basis
of its investment in Immunex and certain transaction costs.
- $1,454.6 ($943.4 after-tax or $0.71 per share-diluted)
recorded during the 2002 fourth quarter relating to the gain
on the sales of 67,050,400 shares of Amgen common stock. The
gain was determined by comparing the basis of the shares sold,
$1,782.7, with the net proceeds received, $3,250.8, reduced by
certain related expenses.
For further details related to the items listed in the table above, refer
to the discussion of "2002, 2001 and 2000 Unusual Transactions" herein.
On January 1, 2002, the Company adopted SFAS No. 142, which eliminated the
amortization of goodwill. Excluding the after-tax goodwill amortization of
$153.9 million or $0.12 per share-diluted from the 2001 results, as well as the
2002 and 2001 unusual items listed in the table above, income and diluted
earnings per share from continuing operations in 2002 each decreased 3% to
$2,962.6 million and $2.22, respectively, compared with $3,054.2 million and
$2.30 in 2001, respectively. The decreases were due primarily to higher cost of
goods sold, as a percentage of net revenue, and higher research and development
expenses, offset by lower selling, general and administrative expenses and
higher other income, net.
The higher cost of goods sold, as a percentage of net revenue, is
attributable to a change in product mix and the costs of addressing various
manufacturing issues. The less profitable product mix was primarily a result of
decreased sales of higher margin products, including the Premarin family and
Prevnar, and higher sales of lower margin products such as Protonix and ReFacto.
The lower selling, general and administrative expenses were due to
cost-containment efforts. Higher other income, net was primarily a result of the
Company completing the sale of certain of its assets relating to the generic
human injectables product line, which resulted in a pre-tax gain of $172.9
million ($108.9 million after-tax or $0.08 per share-diluted). In addition, the
Company received proceeds from a settlement regarding price fixing by certain
vitamin suppliers offset, in part, by lower equity income and the non-recurrence
of income received in 2001 related to the divestiture of certain product rights.
Wyeth 61
Excluding all unusual items from the 2001 and 2000 results listed in the
table above and including the $0.02 per share dilutive effect of common stock
equivalents in the 2000 results, both income and diluted earnings per share from
continuing operations in 2001 increased 15% compared with 2000. The increases
were due primarily to higher U.S. pharmaceutical net revenue and higher other
income, net offset, in part, by higher selling, general and administrative
expenses, research and development expenses, and interest expense, net.
DISCONTINUED OPERATIONS
On June 30, 2000, the Company announced that it had completed the sale of the
Cyanamid Agricultural Products business to BASF Aktiengesellschaft (BASF). Under
the terms of the definitive agreement, BASF paid the Company $3,800.0 million in
cash and assumed certain debt. As a result, the Company recorded an after-tax
loss on the sale of this business of $1,573.0 million or $1.20 per share-diluted
and reflected this business as a discontinued operation beginning in the 2000
first quarter and restated all prior periods presented (see Note 2 to the
consolidated financial statements).
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The consolidated financial statements are presented in accordance with
accounting principles that are generally accepted in the United States. All
professional accounting standards effective as of December 31, 2002 have been
taken into consideration in preparing the consolidated financial statements. The
preparation of the consolidated financial statements requires estimates and
assumptions that affect the reported amounts of assets, liabilities, revenues,
expenses and related disclosures. Some of those estimates are subjective and
complex, and, consequently, actual results could differ from those estimates.
The following accounting policies have been highlighted as significant because
changes to certain judgments and assumptions inherent in these policies could
affect the Company's consolidated financial statements.
- Rebates and sales incentives, which are deducted to arrive at net
revenue, are offered to customers based upon volume purchases, the
attainment of market share levels, government mandates, coupons and
consumer discounts. Rebates and sales incentives accruals, included
in accrued expenses, are established at the later of a) the date at
which the related revenue is recorded or b) the date at which the
incentives are offered. The Company continually monitors the
adequacy of the accruals by comparing the actual payments to the
estimates used in establishing the accrual.
- The Company is involved in various legal proceedings, including
product liability and environmental matters that arise from time to
time in the ordinary course of business. These include allegations
of injuries caused by drugs and other over-the-counter products,
including Pondimin, Redux, Dimetapp and Prempro, among others. The
estimated costs the Company expects to pay in these cases are
accrued when the liability is considered probable and the amount can
be reasonably estimated. In assessing the estimated costs, the
Company considers many factors, including past litigation
experience, scientific evidence and the specifics of each matter.
The Company is self-insured against ordinary product liability risks
and has liability coverage, in excess of certain limits and subject
to certain policy ceilings, from various insurance carriers. Product
liability accruals are not reduced for expected insurance
recoveries.
In addition, the Company has responsibility for environmental,
safety and cleanup obligations under various local, state and
federal laws, including the Comprehensive Environmental Response,
Compensation and Liability Act, commonly known as Superfund. In many
cases, future environmental-related expenditures cannot be
quantified with a reasonable degree of accuracy. As investigations
and cleanups proceed, environmental-related liabilities are reviewed
and adjusted as additional information becomes available.
- The Company applies an asset and liability approach to accounting
for income taxes. Deferred tax liabilities and assets are recognized
for the future tax consequences of temporary differences between the
financial statement and tax bases of assets and liabilities using
enacted tax rates in effect for the year in which the differences
are expected to reverse. The recoverability of deferred tax assets
is dependent upon the Company's assessment that it is more likely
than not that sufficient future taxable income will be generated in
the relevant tax jurisdiction to realize the deferred tax asset. In
the event the Company determines future taxable income will not be
sufficient to utilize the deferred tax asset, a valuation allowance
is recorded. As of December 31, 2002, valuation allowances have been
established for certain environmental liabilities and operating
accruals in certain foreign jurisdictions with little or no history
of generating taxable income. In addition, the Company records
deferred income taxes on foreign subsidiaries' earnings that are not
considered to be permanently invested in those subsidiaries.
- As a result of the recent retraction in the global equity markets,
the Company has experienced a significant reduction in the market
value of assets held by the Company's pension plans. The Company's
pension plans' assets also were decreased by the normal annual
benefit payments, which historically have been offset by the
positive actual return on plan assets. In order to mitigate the
decline, the Company made contributions of $875.0 million to the
U.S. pension plans in December 2002. Despite the contributions, the
market value decline is expected to negatively impact pension
expense in 2003. In addition, based on an annual internal study of
actuarial assumptions, the expected long-term rate of return on plan
assets has been decreased by 25 basis points to 9.00%, and the
discount rate has been decreased by 50 basis points to 6.75%. As a
result of these developments, the 2003 net periodic benefit cost for
pensions is anticipated to be approximately $45.0 million to $55.0
million higher than in 2002.
62 Wyeth
The Company also has reviewed the principal actuarial assumptions
relating to its other postretirement plans. In response to the
recent increase in health care costs in the United States, the
Company has kept the health care cost trend rate for 2002 and 2003
at 9.5%. This rate, ultimately, is expected to decrease to 5% for
2006 and remain constant thereafter. In reviewing postretirement
claims data and other related assumptions, the Company believes that
this trend rate appropriately reflects the trend aspects of the
Company's postretirement plans as of December 31, 2002. As a result
of the selection of the health care cost trend rate, the 2003 net
periodic benefit cost for other postretirement benefits is
anticipated to be approximately $15.0 million to $25.0 million
higher than in 2002.
Management has discussed the development and selection of these critical
accounting policies and estimates with the Audit Committee of the Board of
Directors, and the Audit Committee has reviewed the Company's disclosure
presented above.
The Company has not participated in, nor has created, any off-balance
sheet financing or other off-balance sheet special purpose entities, other than
operating leases. In addition, the Company has not entered into any derivative
financial instruments for trading purposes and uses derivative financial
instruments solely for managing its exposure to certain market risks from
changes in foreign currency exchange rates and interest rates.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
CASH AND CASH EQUIVALENTS increased $1,198.9 million, while total debt decreased
by $1,103.7 million in 2002, including the fair value change of the interest
rate swaps. The activity of these cash flows during 2002 related primarily to
the following items:
- Proceeds of $1,005.2 million received as partial consideration for
the Company's Immunex shares in connection with the acquisition of
Immunex by Amgen. The $1,005.2 million relates to the $4.50 per
share the Company received for each Immunex share owned at closing.
Additionally, the Company received 98,286,358 Amgen shares as
additional consideration for the acquisition of Immunex. The Company
sold 67,050,400 of these shares as of December 31, 2002, receiving
proceeds of $3,250.8 million.
- Proceeds of $272.0 million due primarily to improved collections on
outstanding accounts receivables.
- Net marketable securities proceeds of $296.7 million, proceeds from
sales of assets of $798.3 million and proceeds from the exercise of
stock options of $215.4 million.
These proceeds were partially offset by the following cash uses:
- Payments of $1,307.0 million related to the Pondimin (which in
combination with phentermine, a product that was not manufactured,
distributed or sold by the Company, was commonly referred to as
"fen-phen") and Redux litigation. These payments were financed
primarily from borrowing activities. As discussed in Note 14 to the
consolidated financial statements, during 1999, the Company
announced a nationwide class action settlement to resolve litigation
brought against the Company regarding the use of the diet drugs
Redux or Pondimin. Payments to provide settlement benefits, if
needed, may continue for approximately 16 years after final judicial
approval. Payments of $405.0 million were made to establish a
security fund as required by the settlement. Payments made to date
and future payments related to the diet drug litigation are
anticipated to be financed through existing cash resources, cash
flows from operating activities and additional commercial paper
borrowings, as well as term debt financings and international
earnings remitted back to the United States, if necessary.
- Capital expenditures of $1,931.9 million due primarily to new
production capacity expansion worldwide, including biotechnology
facilities, research and development facilities, and the improvement
of compliance of U.S. technical operations and product supply
processes. The Company expects capital expenditures in 2003 to be
slightly lower compared with 2002 spending levels.
- Dividends totaling $1,219.2 million consisting primarily of the
Company's annual common stock dividend of $0.92 per share that
provided the Company's stockholders with an approximate yield of
2.5%.
- Contributions to fund the Company's defined benefit pension plans
totaling $909.6 million.
- An increase in inventories of $185.6 million primarily related to
improved manufacturing output.
- Purchases of common stock for treasury of $113.9 million.
Total debt: At December 31, 2002, the Company had outstanding $8,350.9
million in total debt. The Company's total debt consisted of commercial paper of
$3,787.1 million and notes payable and other debt of $4,563.8 million. Current
debt at December 31, 2002, classified as Loans payable, consisted of:
- $787.1 million of commercial paper that is in excess of the $3,000.0
million credit facility and is supported by $3,946.9 million of
cash, cash equivalents and marketable securities, and
- $17.8 million of other debt that is due within one year.
The portion of commercial paper outstanding at December 31, 2002 supported
by the $3,000.0 million, 364-day credit facility was classified as Long-term
debt since the Company intends, and has the ability, to refinance these
obligations through the issuance of additional commercial paper or through the
use of its $3,000.0 million credit facility.
ADDITIONAL LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCE INFORMATION
At December 31, 2002, the carrying value of cash equivalents approximated fair
value due to the short-term, highly liquid nature of cash equivalents, which
have original maturities of three months or less. Interest rate fluctuations
would not have a significant effect on the fair value of cash equivalents held
by the Company.
In August 2002, following the July 31, 2002 termination of the Company's
$1,000.0 million credit facility (originally a $2,000.0 million credit facility
reduced to $1,000.0 million in March 2002), the Company obtained a new 364-day,
$2,000.0 million credit facility. As a result of the proceeds received from
Wyeth 63
the sales of the Company's Amgen common stock, the committed amount available
under the facility was reduced to zero on December 30, 2002, and the facility
was terminated.
In March 2003, the Company's $3,000.0 million credit facility matured.
Concurrent with this maturity, the Company entered into new credit facilities
totaling $2,700.0 million. These facilities are composed of a $1,350.0 million,
364-day credit facility and a $1,350.0 million three-year credit facility. The
maturity date of any borrowings under the $1,350.0 million, 364-day credit
facility that are outstanding upon its termination in March 2004 is extendible
by the Company for an additional year. The credit facilities contain
substantially identical financial and other covenants, representations,
warranties, conditions and default provisions as the matured facility.
On February 11, 2003, the Company issued $1,800.0 million of Notes. The
issuance consisted of two tranches of Notes, each of which pay interest
semiannually as follows:
- $300.0 million 4.125% Notes due March 1, 2008 with interest payments
on March 1 and September 1
- $1,500.0 million 5.25% Notes due March 15, 2013 with interest
payments on March 15 and September 15
Previously, in March 2001, the Company issued three tranches of Notes in a
transaction exempt from registration under the Securities Act, pursuant to Rule
144A, as follows:
- $500.0 million 5.875% Notes due March 15, 2004
- $1,000.0 million 6.25% Notes due March 15, 2006
- $1,500.0 million 6.70% Notes due March 15, 2011
The interest rate payable on each series of Notes described above is
subject to an increase of 0.25 percentage points per level of downgrade in the
Company's credit rating by Moody's or S&P. However, the total adjustment to the
interest rate for the series of Notes cannot exceed two percentage points. There
is no adjustment to the interest rate payable on each series of Notes for the
first single-level downgrade in the Company's credit rating by S&P. The Company
would incur a total of approximately $12.0 million of additional annual interest
expense for every 0.25 percentage point increase in the interest rate. If
Moody's or S&P subsequently were to increase the Company's credit rating, the
interest rate payable on each series of Notes would be subject to a decrease of
0.25 percentage points for each level of credit rating increase. The interest
rate payable for the series of Notes cannot be reduced below the original coupon
rate of each series of Notes. In the case of the $300.0 million 4.125% Notes,
the $1,500.0 million 5.25% Notes and $1,500.0 million 6.70% Notes, the interest
rate in effect on March 15, 2006 for such Notes will, thereafter, become the
effective interest rate until maturity on March 1, 2008, March 15, 2013 and
March 15, 2011, respectively.
In addition to the Notes issued in February 2003 and March 2001, the
Company has outstanding: $1,000.0 million 7.90% Notes due February 2005 and
$250.0 million 7.25% debentures due March 2023.
As of December 31, 2002, the Company had net debt of $2,489.1 million
which was calculated as total debt of $8,350.9 million reduced by liquid assets
totaling $5,861.8 million which consisted of cash and cash equivalents,
marketable securities, the fair value of the Amgen investment and the security
fund deposit included in Other assets including deferred taxes.
As of December 31, 2002, the Company was in compliance with all debt
covenants. In addition, the Company has not triggered any incremental
contractual obligations in connection with its financial condition or results of
operations.
The Company has a common stock repurchase program under which the Company
is authorized, at December 31, 2002, to repurchase 4,492,460 additional shares
in the future. Depending upon market conditions, among other things, the Company
may make limited repurchases of its common stock to offset stock issuances in
connection with exercises of stock options during 2003.
Management remains confident that cash flows from operating activities and
existing and prospective financing resources will be adequate to fund the
Company's operations, pay opt out settlement payments and fund the nationwide
class action settlement relating to the Redux and Pondimin diet drug litigation,
pay dividends, maintain the ongoing programs of capital expenditures, including
the amount already committed at December 31, 2002 of $823.7 million, and repay
both the principal and interest on its outstanding obligations, without
requiring the disposition of any significant strategic core assets or
businesses.
The following chart discloses contractual cash obligations at December 31,
2002:
(In millions) LESS THAN
Contractual Cash Obligations TOTAL 1 YEAR 1 - 3 YEARS 4 - 5 YEARS OVER 5 YEARS
- --------------------------------------------------------------------------------------------------------------------------
Total debt $8,350.9 $ 804.9 $4,524.4 $1,012.9 $2,008.7
Operating leases 391.1 89.7 133.3 107.8 60.3
- --------------------------------------------------------------------------------------------------------------------------
Total contractual cash obligations $8,742.0 $ 894.6 $4,657.7 $1,120.7 $2,069.0
==========================================================================================================================
64 Wyeth
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company is exposed to market risk from changes in foreign currency exchange
rates and interest rates that could impact its financial position, results of
operations and cash flows. The Company manages its exposure to these market
risks through its regular operating and financing activities and, when deemed
appropriate, through the use of derivative financial instruments. The Company
uses derivative financial instruments as risk management tools and not for
trading purposes. In addition, derivative financial instruments are entered into
with a diversified group of major financial institutions in order to manage the
Company's exposure to non-performance on such instruments.
FOREIGN CURRENCY RISK MANAGEMENT: The Company generates a portion of Net
revenue from sales to customers located outside the United States, principally
in Europe. International sales are generated mostly from international
subsidiaries in the local countries with the sales typically denominated in the
local currency of the respective country. These subsidiaries also incur most of
their expenses in the local currency. Accordingly, most international
subsidiaries use the local currency as their functional currency. International
business, by its nature, is subject to risks, including, but not limited to:
differing economic conditions, changes in political climate, differing tax
structures, other regulations and restrictions, and foreign exchange rate
volatility. Accordingly, future results could be adversely impacted by changes
in these or other factors.
The Company has established programs to protect against adverse changes in
exchange rates due to foreign currency volatility. The Company believes that the
foreign currency risks to which it is exposed are not reasonably likely to have
a material adverse effect on the Company's financial position, results of
operations or cash flows due to the high concentration of sales in the United
States. On January 1, 2002, 12 member countries of the European Union adopted
the Euro as a new common legal currency. Collectively, these countries accounted
for 11% of both 2002 and 2001 worldwide Net revenue. Additionally, the British
Pound Sterling accounted for 5% of both 2002 and 2001 worldwide Net revenue.
INTEREST RATE RISK MANAGEMENT: The fair value of the Company's fixed-rate
long-term debt is sensitive to changes in interest rates. Interest rate changes
result in gains/losses in the market value of this debt due to differences
between the market interest rates and rates at the inception of the debt
obligation. The Company manages this exposure to interest rate changes primarily
through the use of interest rate swaps and strives to maintain a
fixed-to-variable ratio of approximately 1 to 1 on its net debt position,
consistent with the Company's debt management philosophy.
At December 31, 2002, the notional/contract amounts, carrying values and
fair values of the Company's financial instruments were as follows:
CARRYING
NOTIONAL/ VALUE FAIR VALUE
(In millions) CONTRACT -------------------------
DESCRIPTION AMOUNT ASSETS (LIABILITIES)
- --------------------------------------------------------------------------------
Forward contracts(1) $ 697.9 $ 9.3 $ 9.3
Option contracts(1) 1,177.1 (12.2) (12.2)
Interest rate swaps 1,500.0 200.8 200.8
Outstanding debt(2) 8,155.1 (8,350.9) (8,471.8)
================================================================================
(1) If the value of the U.S. dollar were to increase or decrease by 10%, in
relation to all hedged foreign currencies, the net receivable on the
forward and option contracts would decrease or increase by approximately
$87.6.
(2) If the interest rates were to increase or decrease by one percentage
point, the fair value of the outstanding debt would increase or decrease
by approximately $193.3.
The estimated fair values approximate amounts at which these financial
instruments could be exchanged in a current transaction between willing parties.
Therefore, fair values are based on estimates using present value and other
valuation techniques that are significantly affected by the assumptions used
concerning the amount and timing of estimated future cash flows and discount
rates that reflect varying degrees of risk. Specifically, the fair value of
forward contracts and interest rate swaps reflects the present value of the
future potential gain if settlement were to take place on December 31, 2002; the
fair value of option contracts reflects the present value of future cash flows
if the contracts were settled on December 31, 2002; and the fair value of
outstanding debt instruments reflects a current yield valuation based on
observed market prices as of December 31, 2002.
Wyeth 65
CERTAIN FACTORS THAT MAY AFFECT FUTURE RESULTS
PREMPRO/PREMARIN - HRT STUDIES
Two subsets of the Women's Health Initiative (WHI) enrolled a total of 27,000
predominantly healthy postmenopausal women to assess the risks and benefits of
either long-term estrogen replacement therapy (ERT) or long-term hormone
replacement therapy (HRT). The primary endpoint of the WHI study was coronary
heart disease, with invasive breast cancer as the primary adverse outcome
studied. The HRT subset of the WHI study, involving women who received a
combination of conjugated estrogens and medroxyprogesterone acetate (Prempro),
was stopped early (after the patients were followed in the study for an average
of 5.2 years) because, according to the predefined stopping rule, increased
risks of breast cancer and cardiovascular events exceeded the specified
long-term benefits. The study observed an increased incidence of cardiovascular
disease and, over time, breast cancer among women on HRT compared with those on
placebo. The study also observed a reduction in the incidence of hip, vertebral
and other osteoporotic fractures and of colon cancer among women on HRT compared
with those on placebo. The study did not evaluate the use of HRT for the
treatment of menopausal symptoms, the main indications of the product. These
findings provide additional information about the risks of breast cancer and
cardiovascular disease which were identified as potential adverse events in the
labeling for the Company's HRT products. The labeling for Prempro and Premarin
has been revised to reflect this additional information obtained from the WHI
study.
As a result, sales of Prempro and other Premarin family products have been
and will continue to be adversely affected even though the study subset that was
terminated focused on the long-term use of Prempro and did not involve Premarin
(ERT). Based on the most recent available market data, average weekly
prescriptions written for Prempro and Premarin decreased approximately 60% and
30%, respectively, compared with the total weekly prescriptions written during
the eight-week period preceding the termination of the study subset. Prempro
sales (including Premphase) for the year ended December 31, 2002 represented
approximately 4% of consolidated net revenue. Set forth below are individual
product operating results for Prempro/Premphase and Premarin for the years ended
December 31, 2002 and 2001.
The Company also has received two draft manuscripts for review concerning
data from one arm of the Women's Health Initiative Memory Study (WHIMS). This
arm of WHIMS evaluated the use of estrogen plus progestin therapy on the
development of dementia and mild cognitive impairment in a subset of women age
65 and older from the WHI study. In contrast to previous work that suggested a
beneficial effect on memory and cognition, the preliminary analyses of this arm
of WHIMS suggest certain negative findings in a small percentage of the study
participants. Participants in the study were at least 15 years older than the
typical newly menopausal woman. The authors have not yet submitted either
manuscript to a medical journal for peer review and publication. Such peer
review is an essential next step that normally precedes publication of studies
to enhance the reliability from a clinical and scientific perspective. The peer
review process includes verification and additional analyses of the data as well
as modifications and/or clarifications of conclusions. The Company respects this
process and awaits its outcome to better understand this study and its context.
Nevertheless, because there have been public reports about these preliminary
data, the Company believes it is appropriate to disclose this information. Until
the full review process has been completed, it is impossible to determine what
impact these preliminary findings will have on the use of postmenopausal
estrogen plus progestin products. As a result of earlier WHI findings and
changes to product labeling, prescribing patterns have evolved. Most usage of
hormone therapy is in newly menopausal women who are seeking relief of
menopausal symptoms, with more than 90 percent of new prescriptions for these
products written for women younger than 65 years of age. A separate study arm
evaluating the effect of estrogen alone on cognitive function continues. The
Company supports the appropriate use of hormone therapy and will work with the
FDA and other regulatory bodies to determine what implications these studies
have for labeling. Hormone therapy is not indicated for the prevention or
treatment of dementia or mild cognitive impairment.
PREMPRO/PREMPHASE PREMARIN
----------------- -----------------
YEAR ENDED YEAR ENDED
DECEMBER 31, DECEMBER 31,
(In millions) 2002 2001 2002 2001
- --------------------------------------------------------------------------------
Net revenue $ 636.7 $ 887.9 $1,243.2 $1,185.6
Gross profit 546.3 762.9 1,132.1 1,080.8
================================================================================
66 Wyeth
COMPETITION
The Company operates in the highly competitive pharmaceutical and consumer
health care industries. Premarin, the Company's principal conjugated estrogens
product manufactured from pregnant mare's urine, and related products Prempro
and Premphase (which are single tablet combinations of the conjugated estrogens
in Premarin and the progestin medroxyprogesterone acetate) are the leaders in
their categories and contribute significantly to the Company's net revenue and
results of operations. Premarin's natural composition is not subject to patent
protection (although Prempro has patent protection). The principal indications
of Premarin, Prempro and Premphase are to manage the symptoms of menopause and
to prevent osteoporosis, a condition involving a loss of bone mass in
postmenopausal women. Estrogen-containing products manufactured by other
companies have been marketed for many years for the treatment of menopausal
symptoms. During the past several years, other manufacturers have introduced
products for the treatment and/or prevention of osteoporosis. New products
containing different estrogens and/or different progestins than those found in
Prempro and Premphase, utilizing various forms of delivery and having one or
more of the same indications, also have been introduced. Some companies have
attempted to obtain approval for generic versions of Premarin. These products,
if approved, would be routinely substitutable for Premarin and related products
under many state laws and third-party insurance payer plans. In May 1997, the
FDA announced that it would not approve certain synthetic estrogen products as
generic equivalents of Premarin given known compositional differences between
the active ingredient of these products and Premarin. Although the FDA has not
approved any generic equivalent to Premarin to date, Premarin will continue to
be subject to competition from existing and new competing estrogen and other
products for its approved indications and may be subject to generic competition
from either synthetic or natural conjugated estrogens products in the future. At
least one other company has announced that it is in the process of developing a
generic version of Premarin from the same natural source, and the Company
currently cannot predict the timing or outcome of these or any other efforts.
The marketing exclusivity for Cordarone I.V. ended on October 11, 2002,
and, accordingly, sales of Cordarone I.V. materially decreased due to the
introduction of generic products, several of which have been approved by the
FDA. Cordarone I.V. had net sales of $265.2 million during the year ended
December 31, 2002.
The Company received notification from Teva Pharmaceuticals, USA (Teva)
that it has filed an Abbreviated New Drug Application (ANDA) with the FDA
seeking approval to market generic 37.5 mg, 75 mg and 150 mg venlafaxine
extended release capsules, which is the generic name for the Company's product,
Effexor XR. Teva asserts that certain of the Company's patents relating to
venlafaxine extended release capsules, which expire in 2013 and 2017, are either
invalid or not infringed. Teva did not make any allegations as to the Company's
patent covering venlafaxine itself, which expires in June 2008. The Company
intends to vigorously enforce and defend the patents at issue.
The Company also has been informed that Cobalt Pharmaceuticals, Inc.
(Cobalt) has filed an ANDA with the FDA pertaining to ramipril, the generic name
for Altace, which the Company co-promotes with King Pharmaceuticals, Inc.
(King). The allegations in Cobalt's notice relate to a composition of matter
patent for ramipril, which does not expire until October 2008. The allegations
do not relate to a second patent covering ramipril, which expires in January
2005. Cobalt has stated that it is not seeking FDA approval until this second
patent expires in January 2005. The Company has been informed that King and
Aventis, which owns the pertinent patent, intend to vigorously enforce and
defend this patent.
PRODUCT SUPPLY
Enbrel Supply
Market demand for Enbrel is strong; however the sales growth had been
constrained by limits on the existing source of supply. In December 2002, the
retrofitted Rhode Island facility owned by Amgen was completed, and
manufacturing production was approved by the FDA. Consequently, manufacturing
capacity for Enbrel will significantly increase in 2003. Market demand is
expected to continue to grow, and additional manufacturing supply is projected
to be required. In April 2002, Immunex (prior to being acquired by Amgen)
announced it entered into a manufacturing agreement with Genentech, Inc. to
produce Enbrel beginning in 2004, subject to FDA approval. The current plan for
the longer term includes an additional manufacturing facility, which is being
constructed by the Company in Ireland and expansion of the Rhode Island
facility, both of which are expected to be completed during 2005.
Premarin Supply
The Company continues to experience inconsistent results on dissolution testing
of certain dosage forms of Premarin and is working with the FDA to resolve this
issue. Until this issue is resolved, supply shortages of one or more dosage
strengths may continue to occur. Although these shortages may adversely affect
Premarin sales in one or more accounting periods, the Company believes that, as
a result of current inventory levels and the Company's enhanced process
controls, testing protocols and the ongoing formulation improvement project, as
well as reduced demand (see also "Prempro/Premarin-HRT Studies"), overall
Premarin family sales will not be significantly impacted by the dissolution
issues.
Prevnar Supply
Sales of Prevnar have been affected by manufacturing-related constraints on
product availability. The Company is continuing to implement manufacturing
improvements and has allocated additional personnel and equipment to increase
the production of Prevnar. Additional manufacturing capacity, principally in
fill/finish capacity, also will become available in 2003 and beyond. While the
Company's efforts are expected to significantly increase the available supply
for the market in 2003, the manufacturing processes for this product are very
complex, and there can be no assurance that unanticipated manufacturing-related
difficulties will not constrain Prevnar sales in 2003 or beyond.
Wyeth 67
LITIGATION AND CONTINGENT LIABILITIES
The Company is involved in various legal proceedings, including product
liability and environmental matters that arise from time to time in the ordinary
course of business, the most significant of which are described in the Company's
Annual Report on Form 10-K for the year ended December 31, 2001, Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2002, June 30, 2002 and
September 30, 2002, as well as in the 2002 Annual Report on Form 10-K, which
will be filed by March 31, 2003. These include allegations of injuries caused by
drugs, vaccines and over-the-counter products, including Pondimin (which in
combination with phentermine, a product that was not manufactured, distributed
or sold by the Company, was commonly referred to as "fen-phen"), Redux, Dimetapp
and Prempro, among others. In addition, the Company has responsibility for
environmental, safety and cleanup obligations under various local, state and
federal laws, including the Comprehensive Environmental Response, Compensation
and Liability Act, commonly known as Superfund.
The estimated costs that the Company expects to pay in these cases are
accrued when the liability is considered probable and the amount can be
reasonably estimated. In many cases, future environmental-related expenditures
cannot be quantified with a reasonable degree of accuracy. As investigations and
cleanups proceed, environmental-related liabilities are reviewed and adjusted as
additional information becomes available. In addition, the Company is
self-insured against ordinary product liability risks and has liability
coverage, in excess of certain limits and subject to certain policy ceilings,
from various insurance carriers. It is the opinion of the Company that any
potential liability that might exceed amounts already accrued will not have a
material adverse effect on the Company's financial position but could be
material to the results of operations or cash flows in any one accounting
period.
CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor"
for forward-looking statements. This Annual Report, including management's
discussion and analysis set forth herein, as well as our quarterly and special
reports, proxy statements and other information filed with the Securities and
Exchange Commission and other written or oral statements made by us or on our
behalf may include forward-looking statements reflecting our current views at
the time these statements were made with respect to future events and financial
performance. These forward-looking statements can be identified by their use of
words such as "anticipates," "expects," "is confident," "plans," "could,"
"will," "believes," "estimates," "forecasts," "projects" and other words of
similar meaning. These forward-looking statements address various matters,
including:
- our anticipated results of operations, liquidity position, financial
condition and capital resources;
- the benefits that we expect will result from our business activities
and certain transactions we announced or completed, such as
increased revenues, decreased expenses, and avoided expenses and
expenditures;
- statements of our expectations, beliefs, future plans and
strategies, anticipated developments and other matters that are not
historical facts;
- the future impact of presently known trends, including those with
respect to product performance and competition;
- anticipated developments related to Prevnar sales; Prempro/Premarin
performance; competitor ANDA filings for Effexor XR and Altace; and
Enbrel, Premarin and Prevnar product supply; and
- expectations regarding the impact of potential litigation relating
to Prempro; the nationwide class action settlement relating to Redux
and Pondimin; and additional litigation charges related to Redux and
Pondimin, including those for opt outs from the national settlement.
All forward-looking statements address matters involving numerous assumptions,
risks and uncertainties, which may cause actual results to differ materially
from those expressed or implied by us in those statements. Accordingly, we
caution you not to place undue reliance on these forward-looking statements,
which speak only as of the date on which they were made. From time to time, we
also may provide oral or written forward-looking statements in other materials
we release to the public. Additionally, we undertake no obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future developments or otherwise.
Wyeth 68